# Sex-specific genetic and

# transcriptomic liability to neuroticism

Frank R Wendt<sup>1,2,\*</sup>, Gita A Pathak<sup>1,2</sup>, Kritika Singh<sup>3,4</sup>, Murray B Stein<sup>5-7</sup>, Karestan C Koenen<sup>8-10</sup>, John H<br>Krystal<sup>1</sup>, Joel Gelernter<sup>1,2,11,12</sup>, Lea K Davis<sup>3,4</sup>, and Renato Polimanti<sup>1,2,\*</sup>

, Joel Gelernter<sup>2,244,44</sup>, Lea K Davis<sup>9,4</sup>, and Renato Polimanti<sup>4,2,</sup>\*<br>tment of Psychiatry, Yale School of Medicine, New Haven, CT, I<br>Healthcare System, West Haven, CT, USA<br>nn of Genetic Medicine, Department of Medicine  $\begin{array}{c} 1 \\ 2 \\ 3 \end{array}$ t,

<sup>2</sup> VA CT Healthcare System, West Haven, CT, USA<br><sup>3</sup> Division of Genetic Medicine, Department of Me<br>Nashville, TN, USA VA CT Healthcare System, West Haven, CT, USA<br>Division of Genetic Medicine, Department of Medicine, Vanderbilt Univer<br>Jashville, TN, USA<br>Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nash<br>VA San Diago <sup>2</sup> VA CT Healthcare System, West Haven, CT, USA<br><sup>3</sup> Division of Genetic Medicine, Department of Me<br>Nashville, TN, USA<br><sup>4</sup> Vanderbilt Genetics Institute, Vanderbilt Univers<br><sup>5</sup> VA San Diego Healthcare System, Psychiatry Se  $\overline{a}$ 

Vashville, TN, USA<br>Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA<br>VA San Diego Healthcare System, Psychiatry Service, San Diego, CA, USA<br>Department of Psychiatry, University of Cali 7

<sup>4</sup> Vanderbilt Geneti<br><sup>5</sup> VA San Diego Hea<br><sup>6</sup> Department of Ps<sup>7</sup><br><sup>7</sup> Herbert Werthein VA San Diego Healthcare System, Psychiatry Service, San Diego, CA, USA<br>Department of Psychiatry, University of California San Diego, La Jolla, CA, USA<br>Herbert Wertheim School of Public Health and Human Longevity Science, U <sup>5</sup> VA San Diego Healthcare System, Psychiatry Service, San Diego, CA, USA<br>
<sup>6</sup> Department of Psychiatry, University of California San Diego, La Jolla, CA, USA<br>
<sup>7</sup> Herbert Wertheim School of Public Health and Human Longe ° Department of Psychiatry, University of California San Diego, La Jolla, CA, USA<br><sup>7</sup> Herbert Wertheim School of Public Health and Human Longevity Science, Univ<br>Diego, La Jolla, CA, USA<br><sup>8</sup> Broad Institute of MIT and Harva

' Herbert Wertheim School of Public Health and Human Longevity Science, University of California San<br>Diego, La Jolla, CA, USA<br><sup>8</sup> Broad Institute of MIT and Harvard, Stanley Center for Psychiatry Research, Cambridge, MA, U <sup>8</sup> Broad Institute of MIT<br><sup>9</sup> Massachusetts Genera<br>MA, USA<br><sup>10</sup> Harvard School of Pub <sup>9</sup> Broad Institute of MIT and Harvard, Stanley Center for Psychiatry Research, Cambridge, MA, USA<br><sup>9</sup> Massachusetts General Hospital, Psychiatry and Neurodevelopmental Genetics Unit (PNGU), Bost<br>MA, USA<br><sup>10</sup> Harvard Schoo ° Massachusetts General Hospital, Psychiatry and Neurodevelopmental Genetics Unit (PNGU), Boston,<br>MA, USA<br><sup>10</sup> Harvard School of Public Health, Department of Epidemiology, Boston, MA, USA<br><sup>11</sup> Department of Genetics, Yale

MA, USA<br><sup>10</sup> Harvard School of Public Health, Department of Epidemiology, Boston, MA, USA<br><sup>11</sup> Department of Genetics, Yale School of Medicine, New Haven, CT, USA

<sup>11</sup> Harvard School of Public Health, Department of Epidemiology, Boston, MA, USA<br><sup>11</sup> Department of Genetics, Yale School of Medicine, New Haven, CT, USA<br><sup>12</sup> Department of Neuroscience, Yale School of Medicine, New Haven <sup>12</sup> Department of Neuroscience, Yale School of Medicine, New Haven, CT, USA<br>
\* Corresponding authors: Frank R Wendt (frank.wendt@yale.edu; ORCID: <u>http</u><br>
<u>2108-6822</u>) & Renato Polimanti (<u>renato.polimanti@yale.edu</u>; ORCI <sup>11</sup> Department of Neuroscience, Yale School of Medicine, New Haven, CT, USA<br>\* Corresponding authors: Frank R Wendt (<u>frank.wendt@yale.edu</u>; ORCID: <u>http:</u><br>2108-6822) & Renato Polimanti (<u>renato.polimanti@yale.edu;</u> ORCID:  $\frac{1}{2}$ 2108-6822) & Renato Polimanti (renato.polimanti@yale.edu; ORCID: https://orcid.org/0000-0003-0745-

2108-6822) & Renato Polimanti (renato.polimanti@yale.edu; ORCID: https://orcid.org/0000-0003-0745- Short title: Sex-specific multi-omic liability to neuroticism  $\frac{3}{5}$ Keywords: neuroticism, sex-effects, GWAS, TWAS, pituitary gland, biomarkers<br> $1$ 

Background: The presentation, energy, and relative risk of psychiatric disorders displaying prominent<br>bex differences. We performed genome-wide association studies (GWAS) of neuroticism separately in<br>males and females to i by biological search is a transmitted transmitted to propertion in the propertion of properties and ferrences.<br>
By differences. We performed genome-wide association studies (GWAS) of neuroticism separately in<br>
males and fe

males and females to identify sex-specific genetic and transcriptomic profiles.<br>Methods: Neuroticism scores were derived from the Eysenck Personality Inventory Neuroticism scale.<br>GWAS were performed in 145,669 females and Males and females to identify servepending games and females proming profiles.<br>Methods: Neuroticism scores were derived from the Eysenck Personality Inver<br>GWAS were performed in 145,669 females and 129,229 males from the U MERT METHOD METHODS METHODS METHODS METHODS IN THE METHODS (SWAS were performed in 145,669 females and 129,229 males from the UK Biobank considering<br>autosomal and X-chromosomal variation. Two-sided Z-tests were used to tes autosomal and X-chromosomal variation. Two-sided Z-tests were used to test for sex-specific eff<br>discovered loci, genetic correlates (N=673 traits), tissue and gene transcriptomic profiles, and po<br>associations across health discovered loci, genetic correlates (N=673 traits), tissue and gene transcriptomic profiles, and polygenic<br>associations across health outcomes in the Vanderbilt University Biobank (BioVu, 39,692 females and<br>31,268 males). associations across health outcomes in the Vanderbilt University Biobank (BioVu, 39,692 females and<br>31,268 males).<br>Results: The SNP-heritability of neuroticism was not statistically different between males ( $h^2$ =10.6%) a

associations across health outcomes in the Vanderbilt on the Vanderbilt Octomes States and<br>31,268 males).<br>Results: The SNP-heritability of neuroticism was not statistically different between males (h<sup>2</sup>=10.6%) a<br>females (h Results: The SN<br>females ( $h^2$ =11.<br>and rs7299554;<br>loci reached ge Results: The SNP-heritability of neuroticism was not statistically different between males (*h*<sup>2</sup>=10.6%) and<br>females (*h<sup>2</sup>*=11.85%). Four female-specific (rs10736549-CNTN5, rs6507056-ASXL3, rs2087182-MMS22L,<br>and rs729955 females (*h*°=11.85%). Four female-specific (rs10736549*-CNTN5, rs6507056-ASXL3, rs2087182-MMS22L,*<br>and rs72995548*-HSPB2*) and two male-specific (rs10507274*-MED13L* and rs7984597) neuroticism risk<br>loci reached genome-wid loci reached genome-wide significance. Male- and female-specific neuroticism polygenic scores were<br>most significantly associated with "mood disorders" (male OR=1.11,  $P=1.40 \times 10^{-9}$ ; female OR=1.14,<br> $P=6.05 \times 10^{-22}$ ). T most significantly associated with "mood disorders" (male OR=1.11,  $P=1.40 \times 10^{-9}$ ; female OR=1.14,<br> $P=6.05 \times 10^{-22}$ ). They also associated with sex-specific laboratory measures related to erythrocyte coundistribution, most significantly associated with "mood disorders" (male OR=1.11,  $P=1.40 \times 10^{-9}$ ; female OR=1.14,  $P=6.05 \times 10^{-22}$ ). They also associated with sex-specific laboratory measures related to erythrocyte co<br>distribution, a  $P=6.05x10^{-2}$ ). They also associated with sex-specific laboratory measures related to erythrocyte count,<br>distribution, and hemoglobin concentration. Gene expression variation in the pituitary was enriched for<br>neuroticism distribution, and hemoglobin concernstribution. The measurement is the measurement of genetically-regulated transcriptomic changes<br>highlighted the effect of RAB7L1, TEX26, and PLOT1.<br>Conclusions: Through a comprehensive a

neuroticism loci in males (males  $β=0.026$ ,  $P=0.002$ ) and genetically-regulated transcriptomic changes<br>highlighted the effect of RAB7L1, TEX26, and PLOT1.<br>Conclusions: Through a comprehensive assessment of genetic risk has angular the effect of RAB7L1, and PLOT<br>Conclusions: Through a comprehensive assessment c<br>biological processes, this study identified several mol<br>known sex differences in neurotic symptoms and the biological processes, this study identified several molecular pathways that can partially explain the<br>known sex differences in neurotic symptoms and their psychiatric comorbidities.<br>Nown sex differences in neurotic symptom biological processes, this study identified several molecular pathways that can pathway explaint the<br>known sex differences in neurotic symptoms and their psychiatric comorbidities. known sex differences in neurotic symptoms and their psychiatric comorbidities.

NEURON INTERTOR IN THE RETAIL OF THE RETAIL OF THE PROPERTY INTERTMENTING angles<br>anxiety, self-consciousness, irritability, emotional instability, and depression in response to perceived<br>threat or punishment (1). Neurotic analy can consist the constant (1). Neurotic symptoms are shared among psychiatric diagnoses such as<br>posttraumatic stress disorder (PTSD), generalized anxiety disorder (GAD), and major depressive disord<br>(MDD). Due to its t threat or punishment of threat or punishment contraumatic stress disorder (PTSD), generalized anxiety disorder (GAD), and major depressive<br>(MDD). Due to its transdiagnostic characteristics, genome-wide association studies postum of the stress diagnostic characteristics, genome-wide association studies (GWAS) of<br>neuroticism may detect molecular targets relevant across diagnostic categories. Accordingly, genetic<br>factors associated with neurot (MDD). Due to its transmitted that according to its transmitted particle as a meuroticism may detect molecular targets relevant across diagnostic categories. Accordingly, g<br>factors associated with neuroticism may also be a

neuron across associated with neuroticism may also be associated with several psychiatric diagnoses.<br>Biological sex plays a major role in the complexity of this personality trait. In large studies, including<br>those across c Factors and states manimum may also be accounted manipulating pyramine angulation.<br>Biological sex plays a major role in the complexity of this personality trait. In large studies, inclu<br>those across cultural boundaries (2) Biological sex plays a major section and the complete across cultural boundaries (2), women scored higher than men on tests for neuroticism (3,4).<br>These differences were small to moderate depending on the cultural context, These differences were small to moderate depending on the cultural context, but statistical differen<br>persisted regardless of test country (2). This sex difference also extends to the disorders partially<br>overlapping with ne These difference also extends to the disorders partially<br>poverlapping with neurotic symptoms. For example, women score higher than men on indices of GAD,<br>and the lifetime incidence of MDD in women is almost twice that of m persisted regards overlapping with neurotic symptoms. For example, women score higher than men on indices of G<br>and the lifetime incidence of MDD in women is almost twice that of men (5,6). Women are nearly<br>times more likel and the lifetime incidence of MDD in women is almost twice that of men (5,6). Women are nearly fou<br>times more likely than men to develop PTSD also accounting for differences in traumatic experiences<br>(7).<br>The twin and SNPtimes more likely than men to develop PTSD also accounting for differences in traumatic experiences<br>(7).<br>The twin and SNP-heritability (h<sup>2</sup>) of neuroticism range from 30-50% (8) and 6-15% (9-12), respectively.<br>Large GWAS

(7).<br>The twin and SNP-heritability ( $h^2$ ) of neuroticism range from 30-50% (8) and 6-15% (9-12), respectivel<br>Large GWAS conducted in sex-combined cohorts have discovered up to 150 independent SNPs<br>associated with neuroti (\* )<br>The<br>Larg<br>assc<br>diffe Large GWAS conducted in sex-combined cohorts have discovered up to 150 independent SNPs<br>associated with neuroticism (9,11,13-16). These discoveries consistently implicate neuronal gen<br>differentiation as well as serotonergi mbined cohorts have discovered up to 150 independent SNPs<br>1,13-16). These discoveries consistently implicate neuronal genesis and<br>lergic and dopaminergic signaling (14,17). The frontal cortex is<br>of interest for neuroticism associated with neuroticism (9,11,13-16). These discoveries consistently implicate neuronal ger<br>differentiation as well as serotonergic and dopaminergic signaling (14,17). The frontal cortex is<br>frequently identified as a r differentiation as well as serotonergic and dopaminergic signaling (14,17). The frontal cortex is<br>frequently identified as a region of interest for neuroticism and related psychopathologies.<br>Furthermore, the worry and anxi frequently identified as a region of interest for neuroticism and related psychopathologies.<br>Furthermore, the worry and anxiety features of neuroticism appears to be dissociable and repretive distinct ends of the neurotici Furthermore, the worry and anxiety features of neuroticism appears to be dissociable and r<br>two distinct ends of the neuroticism spectrum (14). In combination, these previous studies<br>epidemiologic differences in neuroticism two distinct ends of the neuroticism spectrum (14). In combination, these previous studies inform the epidemiologic differences in neuroticism and provide clues to understanding individual liability to poor mental health a epidemiologic differences in neuroticism and provide clues to understanding individual liability to poor<br>mental health as it relates to negative affect. Despite the known phenotypic and epidemiologic<br>difference by sex, it epidemiologic<br>
epidemiologic difference by sex, it remains unclear if the genetic vulnerability to neuroticism differs across sexes.<br>
Genetic studies of sex differences in neuroticism have been performed on the X-chromosom

mental difference by sex, it remains unclear if the genetic vulnerability to neuroticism differs across sex<br>Genetic studies of sex differences in neuroticism have been performed on the X-chromosome. S<br>genes on the X-chromo Genetic studies of sex differences in neuroticism have been performed on the X-chromosome. Seve<br>genes on the X-chromosome were previously associated with neuroticism including *HS6ST2* (13). X-<br>chromosome variants accounte genes on the X-chromosome were previously associated with neuroticism including *HS6ST2* (13). X-<br>chromosome variants accounted for 0.22-0.43% of the variance in neuroticism depending on the<br>method used to adjust for dose method used to adjust for dose of the X-chromosome by sex (13). Furthermore, sex-stratified X-<br> $\frac{3}{100}$ method used to adjust for dose of the X-chromosome by sex (13). Furthermore, sex-stratified X-<br> $\frac{3}{4}$ 

chromosomal polygenic scores were unable to predict neuroticism highlighting that autosomal<br>chromosomes account for the majority of the sex differences in the heritability of this personality trait.<br>Here, we present the fi Here, we present the first large-scale neuroticism GWAS investigating the genetic component of sex differences. This study describes sex-specific risk loci for neuroticism across the genome. These loci contribute to sex-sp differences. This study describes sex-specific risk loci for neuroticism across the genome. These loci<br>contribute to sex-specific transcriptomic and biomarker profiles relevant for disease etiology involvir<br>neurotic sympto differences. This study describes sex-specific risk loci for neuroticism across the genome. These loci contribute to sex-specific transcriptomic contributions.<br>Contribute relevant for disease experience relevant for disease etials relevant for disease etials relevant for<br>Alternative relevant for disease etials relevant for

# METHODS

# METHODS<br>Discovery Sample and Neuroticism Definition

 $\begin{array}{c} \n\frac{1}{2} \quad \text{and} \quad \frac{1}{2} \quad \text{and} \quad \frac{$ The UKB is a population based control of ULJ of participants between 2012 particle at the time and the time<br>of recruitments, circulating biomarkers, and sociodemographic characteristics. The UKB consists of<br>273,366 female of the reasurements, circulating biomarkers, and sociodemographic characteristics. The UKB consists<br>273,366 female and 229,114 male participants classified into six ancestry groups.<br>The neuroticism score was derived from 1

273,366 female and 229,114 male participants classified into six ancestry groups.<br>The neuroticism score was derived from 12 neurotic behavior questions from the Eysenck Persona<br>Inventory Neuroticism scale (18,19). At the t The neuroticism score was derived from 12 neurotic behavior questions from the<br>Inventory Neuroticism scale (18,19). At the time of their baseline survey, participa<br>answer each question with "yes," "no," "do not know," or " Inventory Neuroticism scale (18,19). At the time of their baseline survey, participants were asked to<br>answer each question with "yes," "no," "do not know," or "prefer not to answer." Neuroticism questio<br>were: "Does your mo In the time weat and the time of the time of the time of the time party party and the time of times and an answer each question with "yes," "no," "do not know," or "prefer not to answer." Neuroticism quest<br>were: "Does your were: "Does your mood often go up and down?", "Do you ever feel 'just miserable' for no reason?", "Are<br>you an irritable person?", "Are your feelings easily hurt?", "Do you often feel 'fed-up'?", "Would you call<br>yourself a were: "Does your mood often go up and down?", "Do you ever feel 'just miserable' for no reason?", "Are<br>you an irritable person?", "Are your feelings easily hurt?", "Do you often feel 'fed-up'?", "Would you call<br>yourself a you an irritable person?", "Are your feelings easily hurt?", "Do you often feel 'fed-up'?", "Would you call<br>yourself a nervous person?", "Are you a worrier?", "Would you call yourself tense or 'highly strung'?",<br>"Do you wo yourself a nervous person?", "Are you a worrier?", "Would you call yourself tense or 'highly strung'?",<br>"Do you worry too long after an embarrassing experience?", "Do you suffer from 'nerves'?", "Do you<br>often feel lonely?" "Do you worry too long after an embarrassing experience?", "Do you suffer from 'nerves'?", "Do you<br>often feel lonely?", "Are you often troubled by feelings of guilt?". The neuroticism score is the sum of<br>"yes" responses pe often feel lonely?", "Are you of guilt and transfer troubled by guilt?". The neutron called the sum of all<br>"yes" responses per participant and ranges from 0-12 with 12 being the most severe (UKB Field ID<br>20127).<br>Genome-wid "yes" responses per participant and ranges per participant and ranges from 0-12 with 12 being the most severe (UKB Field ID  $\sim$  12 being severe (UKB Field ID  $\sim$  12 being severe (UKB Field ID  $\sim$  12 being severe (UKB Fi 20127).<br>Genome-wide Association with Neuroticism<br>Genotyping and imputation of the UKB have been previously described (20). Briefly, UKB participants

# Genome-wide Association with Neuroticism

(<br>(<br>| were genotyped using a custom Axiom array capturing genome-wide genetic variation and short<br>insertion/deletions, including coding variants and markers providing good coverage for imputation<br>4 insertion/deletions, including coding variants and markers providing good coverage for imputation in inserting coding variants and markers providing good coverage for imputation in<br>4

European ancestry populations. The Haplot analysing the Haplotype Reference Consorting panel.<br>Dur GWAS were restricted to unrelated participants of European ancestry as identified by a two-stage<br>ancestry assignment and pru r<br>Our G\<br>ancest<br>https:/<br>with in ancestry assignment and pruning procedure from the Pan-UKB (details available at<br>https://pan.ukbb.broadinstitute.org/). Linear regression was performed in PLINK-2.0 (21) using SNPs<br>with imputation INFO scores >0.8, minor https://pan.ukbb.broadinstitute.org/). Linear regression was performed in PLINK-2.<br>with imputation INFO scores >0.8, minor allele frequencies >0.01, missingness <0.0.<br>Weinberg equilibrium P-values >1x10<sup>-10</sup>. We included a with imputation INFO scores >0.8, minor allele frequencies >0.01, missingness <0.05, and Hardy-Weinberg equilibrium P-values >1x10<sup>-10</sup>. We included age and the first 15 within-ancestry principal components as covariates. Weinberg equilibrium P-values >1x10 <sup>20</sup>. We included age and the first 15 within-ancestry principal<br>components as covariates. After quality control, we analyzed genetic data from 145,669 females ar<br>129,229 males.<br>X-chromo

X-chromosome association tests were performed using XWAS v3.0 (22). X-chromosome SNPs were components as covariants as covariants as covariants as covariants as control.<br>
29,229 males.<br>
29, Chromosome association tests were performed using XWAS v3.0 (22). X-chromosome SNPs were<br>
20,05 and were not significantly 229,229 march<br>X-chromosome<br>included in the a<br>males and fema<br>performed using Included in the analysis if they had minor allele frequencies >0.05 and were not significantly differe males and females (P<0.05) or missingness <0.05 per sex. Sex-stratified genetic association analysis performed using PL males and females (P<0.05) or missingness <0.05 per sex. Sex-stratified genetic association analysis was<br>performed using PLINK X-chromosome model 2 which codes male X-chromosomal genotypes as 0/2<br>corresponding to the femal performed using PLINK X-chromosome model 2 which codes male X-chromosomal genotypes as 0/2<br>corresponding to the female homozygote state (23).<br>Cross-Ancestry Polygenic Scoring performed using the female homozygote state (23).<br> **Cross-Ancestry Polygenic Scoring**<br> **Cross-Ancestry Polygenic Scoring** 

# Cross-Ancestry Polygenic Scoring

PRSice-v2 (24) was used to test the cross-ancestry portability of polygenic scores (PGS) derived from<br>male- and female-stratified GWAS of neuroticism. Linkage disequilibrium-independent SNPs were )<br>|<br>}<br>} male- and female-stratified GWAS of neuroticism. Linkage disequilibrium-independent SNPs were<br>ascertained based on the 1000 Genomes Project (1kGP) European reference using  $r^2$ =0.01 in 250-kb<br>windows. Regression models w ascertained based on the 1000 Genomes Project (1kGP) European reference using  $r^2$ =0.01 in 250-k<br>windows. Regression models were covaried with age and the first ten principal components of and<br>in the target population. T windows. Regression models were covaried with age and the first ten principal com<br>in the target population. Ten P-value thresholds ( $P_T$ ) were tested: 1, 0.5, 0.3, 0.1, 0.1<br>1x10<sup>-5</sup>, 5x10<sup>-6</sup>, 5x10<sup>-7</sup>, and 5x10<sup>-8</sup>. Five 2 onents of ances<br>5, 0.005, 5x10<sup>-4</sup>,<br>s available at<br>emales), Admixe in the target population. Ten *P*-value thresholds  $(P_T)$  were tested: 1, 0.5, 0.3, 0.1, 0.05, 0.005, 5x10<sup>-4</sup>, 1x10<sup>-5</sup>, 5x10<sup>-6</sup>, 5x10<sup>-7</sup>, and 5x10<sup>-8</sup>. Five populations from the Pan-UKB analysis (details available at h in the target population. Ten P-value thresholds (P<sub>T</sub>) were tested: 1, 0.5, 0.3, 0.1, 0.05, 0.005, 5x10<sup>-</sup>, 1x10<sup>-5</sup>, 5x10<sup>-6</sup>, 5x10<sup>-7</sup>, and 5x10<sup>-8</sup>. Five populations from the Pan-UKB analysis (details available at htt 1x10 °, 5x10 °, 5x10 ′, and 5x10 °. Five populations from the Pan-UKB analysis (details available at<br>https://pan.ukbb.broadinstitute.org/) were tested: African (1,757 males and 2,505 females), Adm<br>American (252 males and 4 American (252 males and 459 females), Central/South Asian (2,704 males and 2,283 females), East Asian<br>(573 males and 1,087 females), and Middle Eastern (537 males and 406 females). American (252 martican and 122 central (2,704 martican (2,704 martican 2,2004 males and 1,087 females), and Middle Eastern (537 males and 406 females).<br>Linkage Disequilibrium Score Regression (LDSC)

# Linkage Disequilibrium Score Regression (LDSC)

Observed-scale heritability ( $h^2$ ) was calculated for each GWAS using LDSC (25) with the 1kGP European |
|
| Observed-scale heritability (*h*<sup>2</sup>) was calculated for each GWAS using LDSC (25) with the 1kGP European<br>ancestry reference LD panel. LDSC also was used to calculate the genetic correlation (*r<sub>g</sub>*) between (i)<br>5 ancestry reference LD panel. LDSC also was used to calculate the generic correlation (rg) between (i)  $\frac{1}{2}$ 

male and female neuroticism score CMA and (ii) a substitute of female neutron female in the male or feeds seen statistics from the UKB (details available at<br>https://github.com/Nealelab/UK\_Biobank\_GWAS) with significant SNP https://github.com/Nealelab/UK\_Biobank\_GWAS) with significant<br>male- and female-specific traits so that each  $r_g$  could be assessed a<br>was applied using the false discovery method (FDR<5%) considering<br>phenotypes=1,346 total https://github.com/Nealelab/UK\_Biobank\_GWAS) with significant SNP-*h*<sup>2</sup> in either sex. We excluded<br>male- and female-specific traits so that each  $r_g$  could be assessed across sex. Multiple testing correcti<br>was applied us male- and female-specific traits so that each rg consider across some train mangele someon was applied using the false discovery method (FDR<5%) considering all trait pairs tested: 2 sexes x 673<br>phenotypes=1,346 total  $r_g$ 

phenotypes=1,346 total  $r_g$  tested.<br>To test which functional categories contribute to the  $h^2$  of neuroticism, we used LDSC to partition each  $h^2$  estimate using 118 genomic annotations. All genomic annotations for part To test which functional categories<br> $h^2$  estimate using 118 genomic annotascribed previously (26-28) and in<br>values derived from partitioned  $h^2$ To test which functional categories contribute to the  $h^2$  of neuroticism, we used LDSC to partition each  $h^2$  estimate using 118 genomic annotations. All genomic annotations for partitioned  $h^2$  have been described pr  $h^2$  estimate using 118 genomic annotations. All genomic annotations for partitioned  $h^2$  have been<br>described previously (26-28) and in the Supplementary Material. Because of the nature of the test, pestimate using 118 genomic annotations. All genomic annotations for partitioned  $h^2$  have been<br>escribed previously (26-28) and in the Supplementary Material. Because of the nature of the test<br>lues derived from partitione values derived from partitioned *h*<br>(26).<br>Functional Annotation of Risk Loci multiple regressions were not subjected to multiple testing corrections<br>  $\label{eq:1} \frac{1}{\sqrt{2\pi}}\int_{0}^{\infty}e^{-\frac{1}{2}(\omega-\omega)}\frac{1}{\omega}\int_{0}^{\infty}e^{-\frac{1}{2}(\omega-\omega)}\frac{1}{\omega}\int_{0}^{\infty}e^{-\frac{1}{2}(\omega-\omega)}\frac{1}{\omega}\int_{0}^{\infty}e^{-\frac{1}{2}(\omega-\omega)}\frac{1}{\omega}\int_{0}$ 

## $\mathsf F$ unctional Annotation of Risk Loci $\mathsf F$ Functional Annotation of Risk Loci

(26).<br>Functional Annotation of Risk Loci<br>Neuroticism liability loci were positionally mapped with Multi-marker Analysis of GenoMic Annotation<br>(MAGMA v1.08) implemented in FUMA v1.6a (29) using 2-kb positional mapping aroun (MAGMA v1.08) implemented in FUMA v1.6a (29) using 2-kb positional mapping around each lead SNP<br>(30). Linkage disequilibrium independent genomic risk loci are defined by their lead SNP (P<5x10<sup>-8</sup>) and<br>all surrounding SNP (30). Linkage disequilibrium independent genomic risk loci are defined by their lead SNP ( $P<5x10^{-8}$ ) and all surrounding SNPs with  $r^2>0.6$  with the lead SNP. Enrichment of tissue transcriptomic profiles was tested re (30). Linkage disequilibrium independent genomic risk loci are defined by their lead SNP (P<5x10 °) and<br>all surrounding SNPs with r<sup>2</sup>>0.6 with the lead SNP. Enrichment of tissue transcriptomic profiles was<br>tested relative types or cell-types tested in both sexes. all surrounding SNPs with  $r^2$ >0.6 with the lead SNP. Enrichment of tissue transcriptomic profiles was tested relative to GTEx v8. Multiple testing correction was applied using FDR (5%) considering all tissue-

# PGS in BioVu

Phenome-wide (PheWAS) and lab-wide association studies (LabWAS) of neuroticism polygenic scores<br>(PGS) were performed in a sex-stratified manner. Neuroticism polygenic scores with continuous |
|
|
| (PGS) were performed in a sex-stratified manner. Neuroticism polygenic scores with continuous<br>shrinkage were calculated for BioVU participants using PRS-CS (31). PRS-CS is a Bayesian polygenic<br>prediction method that impose (PCS) were performed in a search manner manner. Neuroticism polygeme certer man centure in<br>shrinkage were calculated for BioVU participants using PRS-CS (31). PRS-CS is a Bayesian polyger<br>prediction method that imposes con shrinkage were calculated for BioVU participants along the SEC (32). The SEC is a Bayesian prediction method that imposes continuous shrinkage priors on SNP effect sizes. LD-independent S<br>were selected based on the 1kGP Eu

prediction method in the UKGP European ancestry reference panel (31,32).<br>Female- and male-specific PGS were associated with diagnoses, symptoms, and lab measurements<br>measured on European ancestry patients treated at the Va Female- and male-specific PGS were associated with diagnoses, symptoms, an<br>measured on European ancestry patients treated at the Vanderbilt University<br>Phenotypes were extracted from electronic health records (EHRs) and gen Ferrican measured on European ancestry patients treated at the Vanderbilt University Medical Center.<br>Phenotypes were extracted from electronic health records (EHRs) and genetic data was available w<br>6 measured on European ancestry patients transfer at the Vanderbilt University Medical Center.<br>Phenotypes were extracted from electronic health records (EHRs) and genetic data was available for the Vanderbilt University Medi Phenotypes were extracted from electronic health records (EHRs) and genetic data was available within

a biobank lined to the HER called BioVU. Phenotypes in the EHR are represented as phecodes, which<br>represent binary hierarchical clustering of the International Classification of Diseases (ICD9/ICD10) codes<br>(33,34). A minim represent binary instantonal clustering of the International Clustering Creater (Fee (Fee (1990) controlled (33,34). A minimum number of 100 cases were required for inclusion in our PheWAS and a minimum of 100 individuals) (33,34). A minimum of 100 individuals) and 1,136 phecodes within the males are required a minimum of 100 individuals with a measurement that passed quality control (32) for a given laboratory test to be included in the Lab up to 31,785 individuals) and 1,136 phecodes within the female-specific strata (up to 40,417 individuals<br>We required a minimum of 100 individuals with a measurement that passed quality control (32) for a<br>given laboratory t up to 31,368 individuals) and 303 labs in the female-stratified analysis (up to 39,692<br>individuals). We employed the PheWAS package in R (see https://github.com/PheWAS/PheWAS) to<br>parform linear or locitie regression to ide given laboratory test to be included in the LabWAS. We then tested 299 labs in the male-stratified<br>analysis (up to 31,268 individuals) and 303 labs in the female-stratified analysis (up to 39,692<br>individuals). We employed given and the to 31,268 individuals) and 303 labs in the female-stratified analysis (up to 39,692<br>individuals). We employed the PheWAS package in R (see https://github.com/PheWAS/PheWAS) to<br>perform linear or logistic regre individuals). We employed the PheWAS package in R (see https://github.com/PheWAS/PheW<br>perform linear or logistic regression to identify the labs and phecodes that were associated w<br>neuroticism PGS after adjusting for age a individuals). The Photon is the PheCodes that were associated with<br>neuroticism PGS after adjusting for age and the top ten principal components from genetic data to<br>control for population stratification. For LabWAS and Phe perform and the top ten principal components from genetic data-<br>control for population stratification. For LabWAS and PheWAS, multiple testing correction was ap<br>by sex using FDR (5%) to account for the correlation among ph control for population stratification. For LabWAS and PheWAS, multiple testing correction was applied<br>by sex using FDR (5%) to account for the correlation among phecodes. control for population stratification. For LabOntrol MAS and PhenOdes.<br>By sex using FDR (5%) to account for the correlation among phecodes.<br>Transcriptome-wide Association Study (TWAS) in Frontal Cortex and Pituitary

# Transcriptome-wide Association Study (TWAS) in Frontal Cortex and Pituitary

by sex using FDR (5%) to account for the correlation among phecodes.<br>Transcriptome-wide Association Study (TWAS) in Frontal Cortex and I<br>Summary-based TWAS of neuroticism was performed with FUSION (35 Summary-based TWAS of neuroticism was performed with FUSION (35). FUSION predicts the<br>relationship between gene expression and a trait using a linear combination of GWAS Z-statistics and a<br>set of functional weights derived produces the largest  $R^2$  between predicted and observed expression. Multiple testing correction was Features in the prefrontal cortex were based on 118 samples and weights for 4,402 features in the<br>pituitary were based on 157 samples. For each gene, weights are derived from one of five models<br>produces the largest  $R^2$  pituitary were based on 157 samples. For each gene, weights are derived from one of five models t<br>produces the largest  $R^2$  between predicted and observed expression. Multiple testing correction w<br>applied using a stringe produces the largest  $R^2$  between predicted and observed expression. Multiple testing correction was<br>applied using a stringent Bonferroni threshold ( $P < 1.59 \times 10^{-5} = 0.05/3,144$  genes for prefrontal cortex and<br> $P < 1.14 \$ produces the largest *R*° between predicted and observed expression. Multiple testing correction was<br>applied using a stringent Bonferroni threshold (P<1.59x10<sup>-5</sup>=0.05/3,144 genes for prefrontal cortex ar<br>P<1.14x10<sup>-5</sup>=0.0 applied using a stringent Bonferroni threshold (P<1.59x10 °=0.05/3,144 genes for prefrontal cortex and<br>P<1.14x10<sup>-5</sup>=0.05/4,402 genes for pituitary).<br>Gene Expression Effects across Developmental Stage

## Gene Expression Effects across Developmental Stage

P<1.14x10 °=0.05/4,402 genes for pituitary).<br>Gene Expression Effects across Developmen<br>To further explore TWAS results in the conte: To further expression in the content of search the further gone expression, the decaying<br>BrainSpan Atlas of the Developing Human Brain (36). BrainSpan consists of postmortem human<br>tissue and fetal specimens. Samples were e Fraince is a consider the Developing Human Atlas of the Devidence of karyogram, microscopic<br>neuronal, or physical malformations, (ii) maternal substance use during pregnancy, (iii) positive for<br>7 the constraints of physical malformations, (ii) maternal substance use during pregnancy, (iii) positive for<br>
7 neuronal, or physical material, (ii) materials, (iii)  $\frac{1}{2}$  positive formations,  $\frac{1}{2}$  positive for  $\frac{1}{2}$ 

Hepatitis B, Hepatitis B, and HIV, and HIV, postnatal evidence of anticome intermediate as  $\frac{1}{2}$ , and the products of exception values (reads per kilobase per million (RPKM)) (37) from the fron cortex and calculated th We used transformed expression values (reads per kilobase per mi<br>cortex and calculated the average expression for all TWAS genes as<br>stage, and region:<br> $log_2(RPKM + 1) = sex + developmental stage +$ cortex and calculated the average expression for all TWAS genes as a function of sex, developmental<br>stage, and region:

 $\log_2(\mathfrak{m} \mathfrak{m} \mathfrak{m} + 1) = s$ ex  $+$  ae ve topmentat stage  $+$   $j$  tomat cortex regio

stage, and region:<br>  $log_2(RPKM + 1) = sex + developmental\ stage + frontal\ cortex\ region$ <br>
We combined expression data from five frontal cortex regions: anterior (rostral) cingulate (medial<br>
prefrontal) cortex, dorsolateral prefrontal cortex, orbital frontal cortex,  $log_2($ <br>We combined exprefrontal) cortex,<br>and the primary m n<br>(m<br>e<br>e prefrontal) cortex, dorsolateral prefrontal cortex, orbital frontal cortex, ventrolateral prefrontal co<br>and the primary motor cortex (36). This tissue selection resulted in 159 frontal cortex tissue sample<br>(N=68 females). prefromal) cortex, dorselateral prefromal cortex, orbital cortex, orbital frontal prefromal cortex, and the primary motor cortex (36). This tissue selection resulted in 159 frontal cortex tissue samples<br>(N=68 females).<br>Sta (N=68 females).<br>Statistical Comparisons Across Sex (N=68 females).<br> **Statistical Comparisons Across Sex**<br>
We evaluated the sex-specificity of a result by comparing the effect estimates (*e.g.,* SNP-*h*<sup>2</sup>, SNP  $\beta$ , PGS

# Statistical Comparisons Across Sex

We evaluated the sex-specificity of a result by comparing the effect estimates (*e.g.*, SNP-*h<sup>2</sup>*),  $\beta$ , or  $r_g$ ) using z-tests for all estimates significant in one sex (FDR<5%) and not nominally signother sex (*P>0.05* , SNP  $\beta$ , PGS<br>nificant in th βther sex (P>0.05):<br>  $Z = \frac{Estimate_{Female} - Estimate_{Male}}{\sqrt{se(Estimate_{Female})^2 + se(Estimate_{Male})^2}}$ <br>
or example, sex-specific risk loci were defined as any locus meeting genome-wide significance

$$
Z = \frac{Estimate_{Female} - Estimate_{Male}}{\sqrt{se(Estimate_{Female})^2 + se(Estimate_{Male})^2}}
$$

other sex (P>0.05):<br>  $Z = \frac{Estimate_{Female} - Estimate_{Male}}{\sqrt{se(Estimate_{Female})^2 + se(Estimate_{Male})^2}}$ <br>
For example, sex-specific risk loci were defined as any locus meeting genome-wide significance<br>
threshold (P<5x10<sup>-8</sup>) in one sex but failing to reach a nomin  $Z = \frac{E}{\sqrt{se(Es)}}$ <br>For example, sex-specific ri<br>threshold (P<5x10<sup>-8</sup>) in one<br>sex. The effect sizes of thes<br>applied to SNP effect sizes,  $e^{(1)}$ <br> $\sin \theta$ <br> $\sin \theta$ <br> $\sin \theta$ <br> $\sin \theta$ threshold ( $P<5x10^{-8}$ ) in one sex but failing to reach a nominal significance threshold ( $P<0.05$ ) in sex. The effect sizes of these loci also were significantly different between sexes. This procedure applied to SNP e threshold (P<5x10 °) in one sex but failing to reach a nominal significance threshold (P<0.05) in the other<br>sex. The effect sizes of these loci also were significantly different between sexes. This procedure was<br>applied t applied to SNP effect sizes,  $h^2$ ,  $r_g$ , and BioVU PheWAS and LabWAS effect estimates. There were no<br>instances of qualitative heterogeneity in analysis results whereby an association survived multiple<br>testing correction applied to SNP effect sizes,  $h^2$ ,  $r_g$ , and BioVU PheWAS and LabWAS effect estimates. There were no<br>instances of qualitative heterogeneity in analysis results whereby an association survived multiple<br>testing correction testing correction in one sex and had a nominally significant (P<0.05) discordant effect in the other sex.<br> ${\bf RESULTS}$ 

# thesting correction in our setting correction in  $\frac{1}{2}$  . The other sex-stratified GWAS of neuroticism in autosomes and X-chromosome Sex-stratified GWAS of neuroticism in autosomes and X-chromosome

 $T = 1.33$ ; Wilcox  $P < 2.2 \times 10^{-16}$ ; Fig S1). d=1.33; Wilcox  $P$ <2.2x10  $^{16}$ ; Fig S1).

There were 9 and 14 genome-wide significant (GWS; P<5x10 °) LD-independent loci identified in male<br>and female GWAS of neuroticism, respectively (Fig 1a, Fig S2, and Tables S1 and S2). The most<br>significantly associated locu and female CMAS of neurons and females in the set of neurons of neurons is analyzed to a gene-dense rs62062288, P=6.06x10<sup>-13</sup>; females rs559552<br>P=3.62x10<sup>-12</sup>) positionally mapped to a gene-dense region of chromosome 17 c significantly associated locus in both sexes (males rs62062288, P=6.06x10<sup>-13</sup>; females rs55955207,<br>P=3.62x10<sup>-12</sup>) positionally mapped to a gene-dense region of chromosome 17 containing targets<br>previously implicated in ot P=3.62x10 <sup>44</sup>) positionally mapped to a gene-dense region of chromosome 17 containing targets<br>previously implicated in other disorders and internalizing psychopathologies such as *CRHR1, ARF*<br>PLEKHM1, and MAPT (among othe

previously implication cannot such that internalizing psychopathologies such as CRHR1, and MAPT (among others).<br>Of the 23 loci associated with neuroticism, six met criteria for sex-specific effects as they (i) met GWS in<br> Of the 23 loci associated with neurotic<br>one sex and were not associated with<br>differences in effect size in males and f<br>rs10507274\*T (*MED13L-C12orf49-RNF* Of the 23 loci associated with neuroticism, six met criteria for sex-specific effects as they (i) met GWS in one sex and were not associated with neuroticism in the other sex ( $P > 0.05$ ) and (ii) had significant differenc differences in effect size in males and females (Fig 1b and Table 1). The two male-specific loci were<br>rs10507274\*T (*MED13L-C12orf49-RNFT2* gene cluster) and rs7984597\*A (intergenic), both of which<br>associated with lower ne rs10507274\*T (*MED13L-C12orf49-RNFT2* gene cluster) and rs7984597\*A (intergenic), both of which<br>associated with lower neuroticism scores. The four female-specific loci were rs10736549\*A (*CNTN5*<br>rs2087182\*G (*MMS22L*), rs6 rs2087182\*G (*MMS22L*), rs6507056\*G (*ASXL3-NOL4* gene cluster), and rs72995549\*A (*CNTN5*), rs2087182\*G (*MMS22L*), rs6507056\*G (*ASXL3-NOL4* gene cluster), and rs72995548\*C (*HSPB2-PIHID. CBO2-PTS* gene cluster). There rs2087182\*G (MMS22L), rs6507056\*G (ASXL3-NOL4 gene cluster), and rs72995548\*C (HSPB2-PIHID2<br>CBO2-PTS gene cluster). There was no evidence of qualitative heterogeneity (i.e., opposite effect<br>directions) among neuroticism ri *CBO2-PTS* gene cluster). There was no evidence of qualitative heterogeneity (i.e., opposite effect directions) among neuroticism risk loci. We did not identify X-chromosomal loci associated with neuroticism by either gen directions) among neuroticism risk loci. We did not identify X-chromosomal loci associated with<br>neuroticism by either genome-wide or chromosome-specific multiple testing correction.<br>The  $h^2$  of neuroticism was 10.6%±0.8

neuroticism by either genome-wide or chromosome-specific multiple testing correction.<br>The  $h^2$  of neuroticism was 10.6%±0.8 in males and 11.9%±0.7 in females ( $P_{\text{diff}}$ =0.220; Fig 1a). The<br>between them supports substanti The  $h^2$  of neuroticism was 10.6%±0.8 in males and 11.9%±0.7 in females ( $P_{\text{diff}}$ =0.220; Fig.<br>between them supports substantial overlap of the polygenic signal:  $r_g$ =0.906,  $P$ =2.40x10<sup>5</sup><br>Cross-Ancestry Polygenic Scorin The  $h^2$  of neuroticism was 10.6%±0.8 in males and 11.9%±0.7 in females ( $P_{\text{diff}}$ =0.220; Fig 1a). The  $r_g$ <br>between them supports substantial overlap of the polygenic signal:  $r_g$ =0.906, P=2.40x10<sup>-278</sup>.<br>Cross-Ancestry P

# Cross-Ancestry Polygenic Scoring

between them supports substantial overlap of the polygenic signal:  $r_g$ =0.906, P=2.40x10 <sup>279</sup>.<br>Cross-Ancestry Polygenic Scoring<br>In both males and females, the neuroticism PGS derived from a European-descent sample as<br>wit with neuroticism in Central/South Asians across almost all thresholds (male N=2,704,  $R^2$ =0.785%,<br>
P=3.46x10<sup>-6</sup>, P<sub>T</sub>=0.3; female N=2,283,  $R^2$ =0.709%, P=4.87x10<sup>-5</sup>, P<sub>T</sub>=0.5; Table S3) with no differences in<br>
the eff with neuroticism in Central/South Asians across almost all thresholds (male N=2,704,  $R^2$ =0.785%,<br>  $P=3.46 \times 10^{-6}$ ,  $P_T=0.3$ ; female N=2,283,  $R^2$ =0.709%,  $P=4.87 \times 10^{-5}$ ,  $P_T=0.5$ ; Table S3) with no difference<br>
the e  $P=3.46x10^{\circ}$ , P<sub>T</sub>=0.3; female N=2,283, R<sup>2</sup>=0.709%, P=4.87x10<sup>-3</sup>, P<sub>T</sub>=0.5; Table S3) with no differences in the effect estimates. Conversely, in the admixed American samples, neuroticism PGS was associated with neur with neuroticism among females (N=459;  $R^2$ =1.60%, P=0.007) but not males (male N=252,  $R^2$ =0.551%<br>P=0.247;  $P_{diff}$ =0.005) in line with the different sample size available in these two groups. No PGS<br>association survived with neuroticism among females (N=459;  $R^{\epsilon}$ =1.60%, P=0.007) but not males (male N=252,  $R^{\epsilon}$ <br>P=0.247;  $P_{\sf diff}$ =0.005) in line with the different sample size available in these two groups. No F<br>association survived mu  $\frac{1}{5}$ Partition is understanding to the different sample sample in the different sample in the different sample association survived multiple testing correction in the other ancestry groups tested.<br>Partitioned Heritability

# association survived multiple testing correction in the other ancestration in the other ance  $\overline{a}$ Partitioned Heritability

Neuroticism SNP-*h*° was partitioned using 119 genomic annotations. Male and female SNP-*h*° were<br>enriched for 10 and 22 genomic annotations (FDR<0.05), respectively. The most significantly enrich<br>annotation from both GWAS annotation from both GWASs was the Genomic Evolutionary Rate Profiling (GERP) neutral rate score<br>(male enrichment=1.88,  $P=5.45 \times 10^{-12}$ ; female enrichment=1.85,  $P=4.15 \times 10^{-18}$ ). As the estimated<br>enrichments in males (male enrichment=1.88,  $P=5.45 \times 10^{-12}$ ; female enrichment=1.85,  $P=4.15 \times 10^{-18}$ ). As the estimated<br>enrichments in males and females were similar (weighted slope=0.982,  $P=1.52 \times 10^{-23}$ , Fig S3), there w<br>no significan (male enrichment=1.88, *P=*5.45x10 <sup>22</sup>; female enrichment=1.85, *P=*4.15x10 <sup>28</sup>). As the estimated<br>enrichments in males and females were similar (weighted slope=0.982, *P=*1.52x10<sup>-23</sup>, Fig S3), the<br>no significant differ enrichments in males and females were similar (weighted slope=0.982, P=1.52x10 <sup>25</sup>, Fig S3), there were<br>no significant differences in enrichment estimates (Table S4).<br>Genetic Correlation

# Genetic Correlation

no significant differences in enrichment estimates (Table S4).<br> **Genetic Correlation**<br>
We tested the  $r_g$  between neuroticism and 673 traits from UKB with  $h^2$  Z-scores>4 in either sex (Table S5). The GWASs of neuroticis We tested the  $r_g$  between neuroticism and 673 traits from UKB with  $h^2$  Z-scores>4 in either sex (Table<br>S5). The GWASs of neuroticism in males and females were genetically correlated with 172 and 330 tra<br>respectively (F respectively (FDR<0.05). In addition to the 12 items contributing to the neuroticism score derivation, the greatest magnitude  $r_g$  for males was "substances taken for depression" (UKB Field ID 20546\_3,  $r_g$ =0.804,  $P=1.25$ greatest magnitude  $r_g$  for males was "substances taken for depression" (UKB Field ID 20546\_3,  $r_g$ =0.804,<br>P=1.25x10<sup>-16</sup>) and for females was "substances taken for anxiety" (UKB field ID 20549\_3,  $r_g$ =0.812,<br>P=8.65x10<sup>-1</sup>  $P=1.25x10^{-16}$ ) and for females was "substances taken for anxiety" (UKB field ID 20549\_3,  $r_g$ =0.812,<br> $P=8.65x10^{-18}$ ). There were no significant differences in  $r_g$  estimates between males and females as the<br>magnitude o P=8.65x10<sup>-18</sup>). There were no significant differences in  $r_q$  estimates between males and females as the magnitude of these estimates strongly overlapped (weighted slope=0.986,  $P=8.15 \times 10^{-234}$ ; Fig S4).

# PGS associations in BioVU

To contextualize our findings with broader clinical consequences, neuroticism PGS derived from sex-<br>stratified GWAS were tested for association with 942 phecodes and 290 lab measures from BioVU. Male- $\begin{array}{c} \n\frac{1}{2} & \frac{1}{2} \\ \n\frac{1}{2} & \frac{1}{$ and female-specific neuroticism PGS were most significantly associated with "mood disorders" (male<br>OR=1.11, P=1.40x10<sup>-9</sup>; female OR=1.14, P=6.05x10<sup>-22</sup>; Fig 2 and Table S6). There were no sex-specific<br>findings with resp

The most significant laboratory measurements associated with neuroticism were erythrocytes in the OR=1.11, P=1.40x10<sup>-</sup>; female OR=1.14, P=6.05x10<sup>-2-</sup>; Fig 2 and Table S6). There were no sex-specific<br>findings with respect to BioVU phecodes.<br>The most significant laboratory measurements associated with neuroticism were The most significant laboratory measuren<br>urine for male PGS ( $\beta$ =-0.035, P=4.15x10<sup>-5</sup><br>P=3.58x10<sup>-8</sup>). The BioVU LabWAS highlight<br>S7). The most significant laboratory measurements associated mathematical method of  $\epsilon$  in the property of the most significant of  $\rho$ =3.58x10<sup>-8</sup>). The BioVU LabWAS highlighted several sex-differentiated lab measures (Table urine for male PGS (*β*=-0.035, *P*=4.15x10<sup>-s</sup>) and triglyceride concentration for female PGS (*β*=0.040,<br>*P=*3.58x10<sup>-8</sup>). The BioVU LabWAS highlighted several sex-differentiated lab measures (Table 2 and T<sub>i</sub><br>57).<br>Fron P=3.58x10 °). The BioVU LabWAS highlighted several sex-differentiated lab measures (Table 2 and Table<br>S7).<br>Frontal Cortex and Pituitary Transcriptomic Profile Enrichment<br>-

# .<br>Fron<br>. Frontal Cortex and Pituitary Transcriptomic Profile Enrichment

 $10$ 

The most significant transcriptomic profiles enriched in GWAS of neuroticism was frontal cortex (BA9;<br>males  $\beta$ =0.025, P=1.93x10<sup>-4</sup>; females  $\beta$ =0.028, P=5.63x10<sup>-5</sup>) and cerebellum (males  $\beta$ =0.015, P=0.010;<br>females males  $β=0.025$ ,  $P=1.93x10^{-4}$ ; females  $β=0.028$ ,  $P=5.63x10^{-5}$ ) and cerebellum (males  $β=0.015$ ,  $P=0.010$ ;<br>females  $β=0.029$ ,  $P=6.61x10^{-6}$ ), respectively (Table S8). There was strong correlation between the mal<br>an

females  $\beta$ =0.029, P=6.61x10<sup>-6</sup>), respectively (Table S8). There was strong correlation between the male<br>and female frontal cortex TWAS (slope=0.951, P=1.03x10<sup>-122</sup>; Fig 3A and Table S9).<br>Three frontal cortex TWAS gene significance in males: *ZHN204P*, *HTR1D*, and *DCAKD* (Table S10). To evaluate the sex-differential<br>expression of each gene, we compared male and female mean expression values from BrainSpan (36).<br>Sex was independently a significance in males: *ZHN204P, HTR1D,* and *DCAKD* (Table S10). To evaluate the sex-differential<br>expression of each gene, we compared male and female mean expression values from BrainSpan (36).<br>Sex was independently ass expression of each gene, we compared male and female mean expression values from BrainSpar<br>Sex was independently associated with *HTR1D* expression in the frontal cortex (*f*=-0.194, *P*=0.02<br>also exhibited an interaction Sex was independently associated with *HTR1D* expression in the frontal cortex ( $\beta$ =-0.194,  $P$ =0.021) but<br>also exhibited an interaction effect between sex and developmental stage ( $\beta$ =0.036,  $P$ =0.007; Fig 3B).<br>There w

Sex was independently associated with *HTR1D* expression in the frontal cortex (*β*=-0.194, *P*=0.021) but also exhibited an interaction effect between sex and developmental stage (*β*=0.036, *P*=0.007; Fig 3B).<br>There was also exhibited an interaction effect between sex and developmental stage ( $\beta$ =0.036, P=0.007; Fig 3B).<br>There was a male-specific enrichment of pituitary transcriptomic profiles (males  $\beta$ =0.026, P=0.002;<br>females  $\beta$ =5. There was a male-specific enrichment of pituitary transcriptomic profiles (males  $\beta$ =0.026, P=0.002;<br>females  $\beta$ =5.48x10<sup>-4</sup>, P=0.477, P<sub>diff</sub>=0.003). To identify genes underlying this sex-differential enrichm<br>we tested females  $β$ =5.48x10<sup>-4</sup>, *P*=0.477, *P<sub>diff</sub>=*0.003). To identify genes underlying this sex-differential enrichment, we tested the predicted expression of 4,402 genes in the pituitary for association with neuroticism.<br>Th we tested the predicted expression of 4,402 genes in the pituitary for association with neuroticism.<br>There was a strong correlation between the pituitary TWAS from males and females (slope=0.980,<br> $P=3.99 \times 10^{-93}$ ; Fig 3C  $P=3.99 \times 10^{-93}$ ; Fig 3C and Table S11) and most overlapping TWAS signal reflects shared effects of the<br>chromosome 17 CRHR1- and WNT3-KANSL1-ARL17A-containing loci often implicated in disorders w<br>internalizing symptoms ( P=3.99x10<sup>-93</sup>; Fig 3C and Table S11) and most overlapping TWAS signal reflects shared effects of the<br>chromosome 17 *CRHR1*- and *WNT3-KANSL1-ARL17A*-containing loci often implicated in disorders wi<br>internalizing symptoms internalizing symptoms (38,39). Three genes detected in males (P<1.14x10<sup>-5</sup>) were not identified in<br>females (P>0.05): RAB7L1 (males: Z=4.56, P=5.00x10<sup>-6</sup>; females Z=-0.045, P=0.964), FLOT1 (males: Z=-<br>4.39, P=1.11x10<sup>-5</sup> internalizing symptoms (38,39). Three genes detected in males  $(P<1.14x10^{-9})$  were not identified in<br>females (P>0.05): RAB7L1 (males: Z=4.56, P=5.00x10<sup>-6</sup>; females Z=-0.045, P=0.964), FLOT1 (males: Z<br>4.39, P=1.11x10<sup>-5</sup>; 4.39, P=1.11x10<sup>-5</sup>; females Z=-0.639, P=0.523), and *TEX26* (males: Z=4.48, P=7.46x10<sup>-6</sup>; females Z=0.986, P=0.267). 4.39, P=1.11x10<sup>-</sup>; females Z=-0.639, P=0.523), and TEX26 (males: Z=4.48, P=7.46x10°; females Z=0.986,<br>P=0.267).<br>**DISCUSSION** 

**DISCUSSION**<br>Although biological sex plays a major role in the presentation of psychiatric symptoms, this variable is Although biological sex plays a major role in the presentation of psychiatric symptoms, the children of the material<br>loci and associated biological processes underlying the well-established differences in neuroticism and<br>p oci and associated biological processes underlying the well-established differences in neuroticism and<br>prevalence of some mental disorders between males and females. Through GWAS and comprehensive<br>in silico analysis, we de prevalence of some mental disorders between males and females. Through GWAS and comprehensive<br>in silico analysis, we demonstrated that the genetics of neuroticism largely overlap between males and<br>females. However, we high in silico analysis, we demonstrated that the genetics of neuroticism largely overlap between males and<br>females. However, we highlighted several exceptions that may be useful to understand the biology<br>underlying the sex dif in since analysis, we demonstrated that the general structure in algely structure material and<br>females. However, we highlighted several exceptions that may be useful to understand the biology<br>underlying the sex difference females. However, we may may be useful to underlying the sex difference for this trait, and eventually develop sex-specific therapies. Our findin extend to biological processes that may partially explain sex differences in extend to biological processes that may partially explain sex differences in the presentation, etiology,<br> $11$  $e^{2\pi i \frac{1}{2} \left( \frac{1}{2} \right)}$  processes that may partially explain sex differences in the presentation, etion,  $e^{2\pi i \frac{1}{2} \left( \frac{1}{2} \right)}$ 

and, a relative risk or psychiatric line produces the prominent risk or papeline (40), including PTSD,<br>Six loci met our strict definition of sex-specificity such that they had genome-wide significant effects<br>neuroticism i Six loci met our :<br>neuroticism in o<br>different effect :<br>rare *de novo* mu neuroticism in one sex but not even nominal association in the other (P>0.05) and had significantly<br>different effect sizes for the two sexes. One male-specific SNP mapped to *MED13L*, a locus harboring<br>rare *de novo* mutat neuroticism in one sex but not even nominal association in the other (P>0.05) and had significantly<br>different effect sizes for the two sexes. One male-specific SNP mapped to *MED13L*, a locus harboring<br>rare *de novo* muta rare de novo mutations associated with intellectual disability and psychopathology (41). Two femalespecific to compete the control material to control material control material material meaging and<br>behaviors (42,43) and autism spectrum disorder (ASD) (44). This locus has garnered considerable<br>attention because its GWAS

We found no risk loci associated with neuroticism on the X-chromosome. Prior studies have identified Xattention because its GWAS effect translates into model organisms of ASD (44).<br>We found no risk loci associated with neuroticism on the X-chromosome. Prior studies have ident<br>chromosomal neuroticism risk loci that survive attention because its CMAS encountances into model organisms of the CMAS.<br>We found no risk loci associated with neuroticism on the X-chromosome. Prior s<br>chromosomal neuroticism risk loci that survive sex-based heterogeneit investigations confer a more global effect on neuroticism with no heterogeneity across sex. The lack of Because of X-chromosomal inheritance patterns (i.e., female X-inactivation and male hemizygosity<br>on this chromosome that associate with an outcome may confer biologically relevant effects (13).<br>lack of significant associat Because of this chromosome that associate with an outcome may confer biologically relevant effects (13). Our<br>lack of significant associations on the X-chromosome suggests that X-chromosomal loci from previous<br>investigation ack of significant associations on the X-chromosome suggests that X-chromosomal loci from previous<br>investigations confer a more global effect on neuroticism with no heterogeneity across sex. The lack of<br>X-chromosome associ investigations confer a more global effect on neuroticism with no heterogeneity across sex. The lack of<br>X-chromosome association may suggest that sex differences in neuroticism arise because of<br>neurodevelopmental and/or ne X-chromosome association may suggest that sex differences in neuroticism arise because of<br>neurodevelopmental and/or neuroplastic effects of sex steroids (45). As a transdiagnostic feature of<br>disorders with internalizing sy major focus of ongoing consortium efforts of study genetic susceptibility to psychiatric disorders. neurodevelopmental and/or neuroplastic effects of study pothesize that X-chromosomal susceptibility loci<br>PTSD, MDD, and GAD may have similar global effects with few sex-specific effects (46). This question<br>major focus of o disorders with internalizing symptoms, we might hypothesize that it internal calceptimity restricts (16). This question is a<br>major focus of ongoing consortium efforts of study genetic susceptibility to psychiatric disorder

major focus of ongoing consortium efforts of study genetic susceptibility to psychiatric disorders.<br>In both sexes, neuroticism PGS from European ancestry participants translated to Central/South Asian<br>UKB participants. How major focus of ongoing consortion efforts of their preservative propertium, to pay interest and the<br>In both sexes, neuroticism PGS from European ancestry participants translated to Central/South A<br>UKB participants. However IN BOTH SERECT THE SERVICE IN BETTEM STREP IN THE PRINCIPAL CONDITION, PRINCIPAL USE THE PRINCIPAL<br>UKB participants. However; PGS poorly translated to African, East Asian, Admixed American, and Midd<br>Eastern populations (47 UKB participants. However, PCB poor, A minimized to African, Carolican, Cambridge, and the studies and<br>participant recruitment from these populations (48).<br>We also tested for genetic overlap in a phenome-wide manner using

participant recruitment from these populations (48).<br>We also tested for genetic overlap in a phenome-wide manner using two approaches. As expecte<br>identified strong positive genetic overlap between neuroticism and mood diso participant restamment from these populations (48).<br>We also tested for genetic overlap in a phenome-wid<br>identified strong positive genetic overlap between ne<br>females but no differences could be detected by sex.<br>genetic arc Identified strong positive genetic overlap between neuroticism and mood disorders among males and<br>females but no differences could be detected by sex. Using a PGS approach that aggregates neuroticism<br>genetic architecture, Females but no differences could be detected by sex. Using a PGS approach that aggregates neuroticism<br>genetic architecture, we identified sex differences in laboratory measures related to urinary red blood<br>cell count (male females but no anti-time to differences in laboratory measures related to urinary red blood<br>genetic architecture, we identified sex differences in laboratory measures related to urinary red blood<br>cell count (male-specific) gell count (male-specific) and red blood cell physical properties (e.g., distribution width, mean<br>corpuscular hemoglobin, etc.; female-specific). In males, urinary blood strongly implies kidney or urinary<br>12 corpuscular hemoglobin, etc.; female-specific). In males, urinary blood strongly implies kidney<br>12 corpuscular hemoglobin, etc.; female-specific). In males, urinary blood strongly implies kidney or urinary or<br>12

infection and may be an indicator of prostate health (49). The protective effect of neuroticism PGS on urinary blood is opposite to literature of a positive relationship between prostate health and neurotic behavior (50), urinary subsective ppear of interations of a person estimation prosection process rather than<br>behavior (50), suggesting the presence of important clinical and environmental factors rather than<br>strong genetic mediation betw

behavior (1993), strong genetic mediation between these traits.<br>In females, neuroticism PGS was associated with lower mean corpuscular volume and lower red blo<br>cell distribution width, two powerful biomarkers of anemia (51 In females, neuroticism PGS was associated with<br>cell distribution width, two powerful biomarker<br>and mental health is strong with studies across<br>symptoms (53) and cognitive impairment (54). cell distribution width, two powerful biomarkers of anemia (51,52). The relationship between anemia<br>and mental health is strong with studies across the lifespan correlating anemia and greater depressive<br>symptoms (53) and c and mental health is strong with studies across the lifespan correlating anemia and greater depressive<br>symptoms (53) and cognitive impairment (54). A study of >50,000 individuals demonstrated that iron-<br>deficient anemias a symptoms (53) and cognitive impairment (54). A study of >50,000 individuals demonstrated that iron-<br>deficient anemias associated with an adjusted hazard ratio of 1.49 and 1.47 for depressive and anxiety<br>disorders, respecti fatigue (56) and depression (57). disorders, respectively. Regardless of iron supplementation, the female participants had a substantially<br>higher incidence of a psychiatric diagnosis compared to male participants (55). Therefore higher<br>neuroticism PGS in w display text performant control of the representation, the female participants of the female participants<br>higher incidence of a psychiatric diagnosis compared to male participants (55). Therefore higher<br>neuroticism PGS in heuroticism PGS in women may prevent common treatment efficacy and exacerbate symptoms<br>fatigue (56) and depression (57).<br>Finally, we investigated transcriptomic profiles of neuroticism in males and females. Consistent v<br>pr

neuron common treatment may prevent common treatment efficiency and emisted symptoms can be<br>fatigue (56) and depression (57).<br>Finally, we investigated transcriptomic profiles of neuroticism in males and females. Consistent Finally, we investigated transcriptomic profiles of neuroticism in males and females. Consistent with<br>prior TWAS of internalizing disorders and their symptoms, loci in the neuroticism GWAS from males an<br>females had a simil Finally, we investigated a materic promet environment in maler and centurity environments and<br>prior TWAS of internalizing disorders and their symptoms, loci in the neuroticism GWAS from males a<br>females had a similar magnit prior of internal and a similar magnitude of association with gene expression in the frontal cortex (58,59). This<br>finding reinforces the effects of executive functioning deficits, cognitive flexibility, and prospective<br>mem finding reinforces the effects of executive functioning deficits, cognitive flexibility, and prospective<br>memory in depression and anxiety symptoms. The *HTR1D* gene exhibited a significant<br>sex×developmental stage effect. finding removes the effect of encoders the HTR1D gene exhibited a significant<br>sexxdevelopmental stage effect. HTR1D encodes the 5-hydroxytryptamine receptor-1D which plays<br>essential role in serotonin signaling and has been memory in depression and annually symptoms. The Final Correlation Egimental Sex-<br>sex-developmental stage effect. HTR1D encodes the 5-hydroxytryptamine receptor-11<br>essential role in serotonin signaling and has been suggeste essential role in serotonin signaling and has been suggested as a possible therapeutic target for<br>depression, though prior studies could not narrow down where in the brain this therapeutic effect may<br>be most relevant (60). depression, though prior studies could not narrow down where in the brain this therapeutic effe<br>be most relevant (60). We demonstrate that in adult frontal cortex, *HTR1D* is more highly expres<br>females than males suggestin depression, though prior studies could not narrow down where in the brain this therapeutic effect may

be most relevant (60). We demonstrate that in adult from strate that in any corporation of the pituitary transcriptomic profile was male-specific. We further evaluated this finding using TWAS in pituitary tissue from GTEx Enrichment of the pituitary transcriptomic profile was male-specific. We further evaluated th<br>using TWAS in pituitary tissue from GTEx and identified three loci with significant effects in m<br>effect in females (P>0.05): RAB using TWAS in pituitary tissue from GTEx and identified three loci with significant effects in males but r<br>effect in females (P>0.05): RAB7L1, TEX26, and FLOT1. RAB7L1 is involved in axon (61) morphology and<br>has been previ effect in females (P>0.05): RAB7L1, TEX26, and FLOT1. RAB7L1 is involved in axon (61) morphology and<br>has been previously associated with schizophrenia, bipolar disorder, neurodegenerative disorders, and<br>another transdiagno effect in females (P-0.03) associated with schizophrenia, bipolar disorder, neurodegenerative disorders, and<br>another transdiagnostic trait: risk-taking (62,63). TEX26 encodes the protein testis expressed 26 and wa<br>recently another transdiagnostic trait: risk-taking (62,63). *TEX26* encodes the protein testis expressed 26 and wa<br>recently associated with obsessive-compulsive disorder (64) in a large international meta-analysis.<br>FLOT1 was upreg and transmitted with obsessive-compulsive disorder (64) in a large international meta-analysis.<br>FLOT1 was upregulated in brains and peripheral blood of major depressive disorder cases (65) and<br>modulates chronic corticoster recently acceptated with observe disorder and peripheral blood of major depressive disorder cases (65) and<br>modulates chronic corticosterone response (66) suggesting it may play a role in disease etiology. In<br>13 modulates chronic corticosterone response (66) suggesting it may play a role in disease etiology. In our<br>13  $\frac{1}{13}$  suggesting it may play a role in discussed in the set of the set of the set of the

study of the pituitary, *FLOT1* was significantly down-regulated suggesting potential inverse predictive<br>power of disease etiology. The link between the gene expression in the pituitary and neuroticism may<br>emphasizes the w power of disease energy. The link between the gene en<sub>l</sub>ocation in the pitular, and neutonlandic-<br>pituitary-adrenal axis, mood, and mental health (67,68), especially as they relate to hormone<br>differences between men and wo emplasizes the well document of the well document principal private relations of the prituitary–adrenal axis, mood, and mental health (67,68), especially as they relate to hormone<br>differences between men and women (69).<br>Th

pitulary–adifferences between men and women (69).<br>Though comprehensively assessing the sex-specificity of neuroticism risk loci and associated b<br>information, this study has several limitations to consider. First, the GTEx Though comprehensively assessing the sex-s<br>information, this study has several limitation<br>result of models including age and sex as co<br>which survive sex-heterogeneity in the GTEx Information, this study has several limitations to consider. First, the GTEx expression weights are the result of models including age and sex as covariates. Therefore, the estimates reported here are those which survive s information, this study has several annual consideration in contribution, the estimates reported here are thos<br>result of models including age and sex as covariates. Therefore, the estimates reported here are thos<br>which sur which survive sex-heterogeneity in the GTEx project. Though we were able to follow up brain results in<br>sex-stratified manner using BrainSpan, future studies will require additional samples to support<br>statistically powerful sex-stratified manner using BrainSpan, future studies will require additional samples to support<br>statistically powerful gene expression studies stratified by sex. Second, sex-stratified studies inherently<br>reduce statistica statistically powerful gene expression studies stratified by sex. Second, sex-stratified studies inh<br>reduce statistical power of a GWAS by separating the total sample. This reduction in sample size<br>prohibitive for GWAS of standary increases the component of a GWAS by separating the total sample. This reduction in sample size may be<br>prohibitive for GWAS of historically excluded populations. The findings from this study further<br>necessitate de reduce statistical power of a GWAS of historically excluded populations. The findings from this study further<br>necessitate dedicated recruitment of women and minorities in studies of mental health (48).<br>Despite these limita

promine for GMAS of historically prediction in studies of mental health (48).<br>Despite these limitations, we report sex-specific genetic and transcriptomic liability to neurotic<br>across multiple complementary analyses. These necessitate academicated remaining of the minorities in standard of minimizing the minorities of mental  $(45)$ .<br>Despite these limitations, we report sex-specific genetic and transcriptomic liability to neurot<br>across multip across multiple complementary analyses. These findings, and the associated sex-specific biomarkers<br>detected here, launch multiple hypotheses for testing and understanding the sex differences in detected here, launch multiple hypotheses for testing and understanding the sex differences in<br>presentation, etiology, and relative risk of psychiatric disorders with debilitating neurotic symptoms.<br><br>A CISA CISA CISA CISA detected here, launch multiple hypotheses for testing and understanding and substitute in<br>presentation, etiology, and relative risk of psychiatric disorders with debilitating neurotic sympt<br>**ACKNOWLEDGEMENTS** 

**ACKNOWLEDGEMENTS**<br>This research was conducted using the UK Biobank Resource (application reference no. 58146). The  $\begin{array}{c} \n\frac{1}{2} & \frac{1}{2} \\ \n\frac{1}{2} & \frac{1}{$ authors thank the research participants and employees of the UK Biobank for making this work possible.<br>This study was supported by the National Institutes of Health (R21 DC018098, R33 DA047527, and F32<br>MH122058) and One Mi This study was supported by the National Institutes of Health (R21 DC018098, R33 DA047527, and F32<br>MH122058) and One Mind.<br>DISCLESION TO RIVING The National Institutes of Health (R21 DC12 DA048) and One Mind.<br>Institutes of Health (R21 DC180988, R33 DA047527, and F32 DA047527, and F32 DA047527, and F32 DA047527, and F3<br>Institute of Health (R21 DC18098, R33 DA047527

**DISCLOSURES**<br>Drs. Gelernter is named as an inventor on PCT patent application #15/878,640 entitled: "Genotype-  $\frac{1}{2}$  filed January 24, 2018. Dr. Stein is paid for his editorial work on the historic control work o

journals Biological Psychiatry and Depression and Anxiety, and the health professional reference Up-To-Datinyx, atai Life Sciences, Boehringer Ingelheim, Bionomics, BioXcel Therapeutics, Eisai, Clexio,<br>EmpowerPharm, Engrail Therapeutics, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and<br>Roche/Genentech. Drs. Polimanti EmpowerPharm, Engrail Therapeutics, GW Pharmaceuticals, Janssen, Jazz Pharmaceuticals, and<br>Roche/Genentech. Drs. Polimanti and Gelernter are paid for their editorial work on the journal C<br>Psychiatry. The other authors have EmpowerPharm, Englisherando ChempowerPharm, Reche/Genentech. Drs. Polimanti and Gelernter are paid for their editorial work on the journal C<br>Psychiatry. The other authors have no competing interests to report.<br>Dr. Krystal' Rochiatry. The other authors have no competing interests to report.<br>Dr. Krystal's financial disclosures are as follows:<br>Consultant (Note: -The Individual Consultant Agreements listed below are less than \$5,000 per year) Psychiatry. The other authors have no competing interests to report.

# Consultant (Note: – The Individual Consultant Agreements listed below are less than \$5,000 per year)

Presence of the sense may be competing interests to report.<br>Dr. Krystal's financial disclosures are as follows:<br>Consultant (Note: - The Individual Consultant Agreements listed be<br>Aptinyx, Inc., Atai Life Sciences, Biogen, Consultant (Note: -The Individual Consultant<br>Aptinyx, Inc., Atai Life Sciences, Biogen, Idec, MA<br>International, Cadent Therapeutics, Inc., Clexio E<br>Kingdom. Concert Pharmaceuticals. Inc.. Epiodvi International, Cadent Therapeutics, Inc., Clexio Bioscience, Ltd., COMPASS Pathways, Limited, United<br>Kingdom, Concert Pharmaceuticals, Inc., Epiodyne, Inc., EpiVario, Inc., Greenwich Biosciences, Inc.,<br>Heptares Therapeutic Xingdom, Concert Pharmaceuticals, Inc., Epiodyne, Inc., EpiVario, Inc., Greenwich Biosciences, Inc.,<br>Heptares Therapeutics, Limited (UK), Janssen Research & Development, Jazz Pharmaceuticals, Inc.,<br>Otsuka America Pharmaceu Heptares Therapeutics, Limited (UK), Janssen Research & Development, Jazz Pharmaceuticals, Inc., Otsuka America Pharmaceutical, Inc., Perception Neuroscience Holdings, Inc., Spring Care, Inc., Sunovion Pharmaceuticals, Inc Heptares Therapeutics, Limited (UT), Januari Meretarian of Development, Jazz Pharmaceuticals, Inc.,<br>Otsuka America Pharmaceutical, Inc., Perception Neuroscience Holdings, Inc., Spring Care, Inc.,<br>Sunovion Pharmaceuticals, Sunovion Pharmaceuticals, Inc., Takeda Industries, Taisho Pharmaceutical Co., Ltd<br>Board of Directors

# Board of Directors

Sunovion Pharmaceuticals, Inc., Takeda Industries, Taisho Pharmaceutical Co., Ltd<br>Board of Directors<br>Freedom Biosciences, Inc.

# Scientific Advisory Board

Freedom Bioschich, 1988<br>Scientific Advisory Board<br>Biohaven Pharmaceuticals Clinical Advisory Board), Cerevel Therapeutics, LLC, Delix Therapeutics, Inc., EpiVario, Inc., Eisai, Inc., I<br>Jazz Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation,<br>PsychoGenics, In (Clinical Advisor), China<br>
Jazz Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation,<br>
PsychoGenics, Inc., Neumora Therapeutics, Inc., Tempero Bio, Inc., Terran Biosciences, Inc.<br>
Stock Jazz Pharmaceuticals, Inc., Neurocrine Biosciences, Inc., Novartis Pharmaceuticals Corporation,<br>PsychoGenics, Inc., Neumora Therapeutics, Inc., Tempero Bio, Inc., Terran Biosciences, Inc.<br>Stock

# Stock

Prices, Inc., Tempero Biohaven Pharmaceuticals, Sage Pharmaceuticals, Spring Care, Inc., Tempero Biohaven Pharmaceuticals, Sage Pharmaceuticals, Spring Care, Inc.  $\begin{array}{c} \begin{array}{c} \begin{array}{c} \end{array} \\ \begin{array}{c} \end{array} \\ \begin{array}{c} \end{array} \\ \begin{array}{c} \end{array} \end{array} \end{array}$ 

# **Stock Options**

Biosciences, Inc., Tempero Bio, Inc.<br>Biosciences, Inc., Tempero Bio, Inc.<br>Income Greater than \$10,000

# Bioscience, Inc., Tempero Bio, Inc.<br>|<br>Biosciences|<br>Editorial Board Income Greater than \$10,000

# |
|
|-Editorial Board

# Patents and Inventions

Editor - Biological Psychiatry<br>
Patents and Inventions<br>
1. Seibyl JP, Krystal JH, Charney DS. Dopamine and noradrenergic reuptake inhibitors in treatment of<br>
schizophrenia. US Patent #:5,447,948.September 5, 1995  $\frac{1}{2}$ 

1. Schizophrenia. US Patent #:5,447,948.September 5, 1995<br>2. Vladimir, Coric, Krystal, John H, Sanacora, Gerard – Glutamate Modulating Agents in the Treatment<br>Mental Disorders. US Patent No. 8,778,979 B2 Patent Issue Date: schiff and the University of the 2.<br>Schizophrenia. US Patent No. 8,778,979 B2 Patent Issu<br>No. 15/695,164:<br>Siling Date: 09/05/2017 2. Vladimir, Corry, Myon, Tommir, Composition, Correct – Christmas in Christmas, Cycle in the Treatment of Mental Disorders. US Patent No. 8,778,979 B2 Patent Issue Date: July 15, 2014. US Patent Application<br>No. 15/695,164

Mo. 15/695,164:<br>Filing Date: 09/05/2017<br>3. Charney D, Krystal JH, Manji H, Matthew S, Zarate C., - Intranasal Administration of Ketamine to Trea<br>Depression United States Patent Number: 9592207. Issue date: 3/14/2017. Marter, 1999<br>Filing Date: 09/0!<br>3. Charney D, Kr<br>Depression Unite<br>Research & Deve Filing Date: 09/09/2020<br>3. Charney D, Krystal JH<br>Depression United State<br>Research & Developmen<br>4. Zarate, C, Charney, DS 3. Depression United States Patent Number: 9592207, Issue date: 3/14/2017. Licensed to Janssen<br>Research & Development<br>4. Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Yale University "Methods for Treati

Besearch & Development<br>Research & Development<br>4. Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Yale University "Methods for Trea<br>Suicidal Ideation", Patent Application No. 15/379,013 filed on December 1 Research & Development<br>4. Zarate, C, Charney, DS, Manji, HK, Mathew, Sanjay J, Krystal, JH, Yale University "Methods for Trea<br>Suicidal Ideation", Patent Application No. 15/379,013 filed on December 14, 2016 by Yale Univers 4. Suicidal Ideation", Patent Application No. 15/379,013 filed on December 14, 2016 by Yale University<br>Office of Cooperative Research<br>5. Arias A, Petrakis I, Krystal JH. – Composition and methods to treat addiction.<br>Provis

Office of Cooperative Research<br>S. Arias A, Petrakis I, Krystal JH. — Composition and methods to treat addiction.<br>Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of<br>Cooperat 5. Arias A, Petrakis I, Krystal JH. – Composition and methods to treat addiction.<br>Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale U<br>Cooperative Research. Provisional Use Patent Application no. 61/973/961. April 2, 2014. Filed by Yale University Office of Provisional Use Patent Application no.61/973/961. April 2, 2014. Filed by Yale University Office of Cooperative Research.

6. Chekroud, A., Gueorguieva, R., & Krystal, JH. "Treatment Selection for Major Depressive Disorder"<br>[filing date 3<sup>rd</sup> June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by<br>Yale University

[filing date 3<sup>.</sup>° June 2016, USPTO docket number Y0087.70116US00]. Provisional patent submission by<br>Yale University<br>7. Gihyun, Yoon, Petrakis I, Krystal JH – Compounds, Compositions and Methods for Treating or<br>Preventing 7. Gihyun, Yoon, Petrakis I, Krystal JH – Compounds, Compositions and Methods for Treating or<br>Preventing Depression and Other Diseases. U. S. Provisional Patent Application No. 62/444,552<br>January10, 2017 by Yale University Preventing Depression and Other Diseases. U.S. Provisional Patent Application No. 62/444,552, filed on

Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 62/719,935 filed on August<br>20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01 8. Abdallah, C, Krystal, JH, Duman, R, Sanacora, G. Combination Therapy for Treating or Preventing 8. Depression or Other Mood Diseases. U.S. Provisional Patent Application No. 62/719,935 filed on Au<br>20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01<br>9. John Krystal, Godfrey Pearlson, Stephanie O'M

20, 2018 by Yale University Office of Cooperative Research OCR 7451 US01<br>9. John Krystal, Godfrey Pearlson, Stephanie O'Malley, Marc Potenza, Fabrizio Gasparini, Baltazar<br>Gomez-Mancilla, Vincent Malaterre. Mavoglurant in t 20, 2018 by Yale University O. 2019<br>20, 2018 by Narc Postal, Godfrey Pearlson, Stephanie O'Malley, Marc Potenza, Fabriz<br>2018 Gomez-Mancilla, Vincent Malaterre. Mavoglurant in treating gambling and<br>2020 Frovisional Patent A Gomez-Mancilla, Vincent Malaterre. Mavoglurant in treating gambling and gaming disorders. U.S.<br>Provisional Patent Application No. 63/125,181filed on December 14, 2020 by Yale University Offic<br>Cooperative Research OCR 8065 Provisional Patent Application No. 63/125,181filed on December 14, 2020 by Yale University Office of Provide Applicative Research OCR 8065 US00<br>Provide all Patent Application No. 63/125,181<br>Provide of the University Office of December 14, 2021<br>Provide of the University Office of the University Office of the University Off

# NON Federal Research Support

AstraZeneca Pharmaceuticals provides the drug, Saracatinib, for research related to NIAAA grant<br>"Center for Translational Neuroscience of Alcoholism [CTNA-4]  $\frac{1}{2}$ 

Center for Translational Neuroscience of Alcoholism [CTNA-4]<br>Astrazeneca Pharmaceutical Pharmaceutical Pharmaceuticals provides the drug, Mayoglurant, for research related to NIAAA grant "Center for Translation<br>Neuroscienc Novartis provides the drug, Mavoglurant, for research related to<br>Neuroscience of Alcoholism [CTNA-4]<br>Cerevel provides the drug PF-06412562 for A Translational and<br>Partial Agonist for Schizophrenia (1 U01 MH121766-01)

Neuroscience of Alcoholism [CTNA-4]<br>Neuroscience of Alcoholism [CTNA-4]<br>Cerevel provides the drug PF-06412562 for A Translational and Neurocomputational Evaluation of a D1<br>Partial Agonist for Schizophrenia (1 U01 MH121766-New continue of Alcoholism [CTNA-4]<br>Cerevel provides the drug PF-0641256<br>Partial Agonist for Schizophrenia (1 UC Partial Agonist for Schizophrenia (1 U01 MH121766-01)<br>Partial Agonist for Schizophrenia (1 U01 MH121766-01)

# Partial Agonist for Schizophrenia (1 U01 MH121766-1)<br>REFERENCES

 $\begin{array}{c} \n\text{1} \\
\text{2} \\
\text{3} \\
\text{4} \\
\text{5} \\
\text{6} \\
\text{7} \\
\text{8} \\
\text{9} \\
\text{10} \\
\text{11} \\
\text{12} \\
\text{13} \\
\text{14} \\
\text{15} \\
\text{16} \\
\text{17} \\
\text{18} \\
\text{19} \\
\text{19} \\
\text{10} \\
\text{10} \\
\text{11} \\
\text{12} \\
\text{13} \\
\text{14} \\
\text{15} \\
\text{16} \\
\text{17} \\
\text{18} \\
\text{19} \\
\text{$  $\frac{1}{2}$ 1. Experimental tanging public health implications. World Psychiatry. 16:144-145.<br>
17. The same of personality with our personality with the personality with the personality with the personality with the personality with t enormous public health implications. World Psychiatry. 16:144-145.

2. Schmitt DP, Realo A, Voracek M, Allik J (2008): Why can't a man be more like a woman? Sex<br>differences in Big Five personality traits across 55 cultures. *J Pers Soc Psychol*. 94:168-182.<br>South SC, Jarnecke AM, Vize CE ( South SC, Jarnecke AM, Vize CE (2018): Sex differences in the Big Five model perso<br>behavior genetics exploration. Journal of Research in Personality. 74:158-165.<br>4. Weisberg YJ, Deyoung CG, Hirsh JB (2011): Gender Differen

3. Solaration Senation Collection Collection of Research in Personality. 74:158-165.<br>
3. South Scheen American Scheen American Scheen American Scheen American Scheen Aspects of the Big Five. Front Psychol. 2:178.<br>
3. Solar

behavior of Reynam CG, Hirsh JB (2011): Gender Differences in Personal Aspects of the Big Five. *Front Psychol.* 2:178.<br>
5. Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, et al. (2018)<br>
DSM-5 Major Depressive D 4. Weisberg Wylden, 2.178.<br>Aspects of the Big Five. *Front Psychol.* 2:178.<br>5. Hasin DS, Sarvet AL, Meyers JL, Saha TD, Ruan WJ, Stohl M, et al. (2018): Epidemiology of Ad<br>DSM-5 Major Depressive Disorder and Its Specifiers

F. Hasin DS, Sarvet AL, Meyers JL, Saha<br>DSM-5 Major Depressive Disorder and Its Spe<br>6. Wendt FR, Pathak GA, Tylee DS, Gosv<br>in Psychiatric Disorders: A Genome-Wide Per 5. Has in the United States. JAMA Psychiatry, 75:336-346.<br>
5. Wendt FR, Pathak GA, Tylee DS, Goswami A, Polimanti R (2020): Heterogeneity and Polygenicity<br>
5. Wendt FR, Pathak GA, Tylee DS, Goswami A, Polimanti R (2020): H DEPRESSIVE DEPRESSIVE DISORDER AND TREP DISPONDED THE UNITED STATES. THE UNITED STATES OF A SUMMON STATES (The<br>
Disponsion Disorder and Its Specifiers: A Genome-Wide Perspective. *Chronic Stress (Thousand Oaks).*<br>
2.247054 in Psychiatric Disorders: A Genome-Wide Perspective. Chronic Stress (Thousand Oaks).<br>4:2470547020924844.<br>7. Polimanti R, Wendt FR (2021): Posttraumatic stress disorder: from gene discovery to disease<br>biology. Psychological

1:2470547020924844.<br>T. Polimanti R, Wendt FR (2021): Posttraumatic stress disorder: from gene discove<br>biology. *Psychological Medicine*. 51:2178-2188.<br>8. Vukasović T, Bratko D (2015): Heritability of personality: A meta-an 4:2470547020924844.<br>
7. Polimanti R, Wendt FR (2021): Posttraumatic stress disorder: from gene discovery to disease<br>
biology. Psychological Medicine. 51:2178-2188.<br>
8. Vukasović T, Bratko D (2015): Heritability of personal

Vukasović T, Bratko D (2015): Heritability of personality: A meta-analysis of behavior genetic

biology.<br>Biology. Parako D (2015): Heritabilit<br>studies. Psychol Bull. 141:769-785.<br>9. Okbay A, Beauchamp JP, Fontana MA, Lassociation study identifies 74 loci associated wi 9. Okbay A, Beauchamp JP, Fontana MA, Lee JJ, Pers TH, Rietveld CA, et al. (2016): Genome-wide<br>association study identifies 74 loci associated with educational attainment. Nature. 533:539-542.<br>10. Power RA, Pluess M (2015) 9. Okbay A, Beauchamp JP, Fc<br>association study identifies 74 loci a<br>10. Power RA, Pluess M (2015)<br>common genetic variants. Transl Ps

association study identifies 74 loci associated with educational attainment. Nature. 533:539-542.<br>10. Power RA, Pluess M (2015): Heritability estimates of the Big Five personality traits based on<br>11. Smith DJ, Escott-Price

association study of the Big Five personality traits based of the Mignon study in the Signal common genetic variants. Transl Psychiatry. 5:e604.<br>11. Smith DJ, Escott-Price V, Davies G, Bailey ME, Colodro-Conde L, Ward J, e 11. Smith DJ, Escott-Price V, Davies G, Bailey ME, Colodro-Conde L, Ward J, et al. (2016): Genom<br>11. Smith DJ, Escott-Price V, Davies G, Bailey ME, Colodro-Conde L, Ward J, et al. (2016): Genom<br>12. Nights for over 1062000 common generic variants. Translating paramy serves in<br>11. Smith DJ, Escott-Price V, Davies G, Bailey ME<br>wide analysis of over 1062000 individuals identifies 9<br>21:749-757.<br>12. Vinkhuyzen AA, Pedersen NL, Yang J, Lee SH,

 $1.81$ . Smith Dig,  $P_0$ ,  $P_1$   $\geq$   $P_1$   $\geq$   $P_2$ ,  $\geq$   $P_3$ wide analysis of 1000 individuals 21:749-757.<br>12. Winkhuyzen AA, Pedersen NL, Yang J, Lee SH, Magnusson PK, Iacono WG, et al. (2012): Cor<br>SNPs explain some of the variation in the personality dimensions of neuroticism and 22:07:25<br>21:25 Vink<br>21:549-757.07<br>21:35 V.02:07 12. Vinkhuyzen AA, Pedersen A<sub>2</sub>, 2013.), angeles A, <sub>Magnus</sub> Common, Massachusette, Pedar<sub>y</sub> 2014.<br>13. Luciano M, Davies G, Summers KM, Hill WD, Hayward C, Liewald DC, et al. (2021): The influence<br>13. Luciano M, Davies G,

Suchiatry. 2:e102.<br>13. Luciano M, Davies G, Summers KM, Hill WD, Hayward C, Liewald DC, et al. (2021): The influence<br>14. Nagel M, Jansen PR, Stringer S, Watanabe K, de Leeuw CA, Bryois J, et al. (2018): Meta-analysis<br>14. N

13. Luciano M,<br>of X chromosome v<br>14. Nagel M, Ja<br>of genome-wide ass 13. Luciano M, David Theory of X chromosome variants on trait neuroticism. *Molecular Psychiatry*. 26:483-491.<br>
14. Nagel M, Jansen PR, Stringer S, Watanabe K, de Leeuw CA, Bryois J, et al. (2018): Meta-analysis<br>
15. Lucia <sup>2</sup><br>14. Nagel M, Jansen PR, Stringer S, Watanabe K, de Leeuw CA, Bryois J, et al. (2<br>16. September – Wide association studies for neuroticism in 449,484 individuals identifier<br>15. Turley P, Walters RK, Maghzian O, Okbay A, 14. Nagel M, Jansen M, January 9, Tanahar PA, and Leemand, Jordy 19. Jordy 19. Jordy 19. And the analysis of genome-wide association studies for neuroticism in 449,484 individuals identifies novel genetic locition<br>15. Turl

of genome-wide association summary statistics using MTAG. Nat Genet. 50:229-237.<br>
Turley P, Walters RK, Maghzian O, Okbay A, Lee JJ, Fontana MA, et al. (2018): Multi-trait analys<br>
of genome-wide association summary statist and pathways. *Nat Genet*. 50:920-927.<br>15. Turley P, Walters RK, Maghzian O, Okbay A, Lee JJ, Fontana MA, et al. (2018): Multi-trait analysis<br>of genome-wide association summary statistics using MTAG. *Nat Genet*. 5 15. Turley P, Walters Representing Section Control of genome-wide association summary statistics using MTAG. Nat Genet. 50:229-237.<br>18 of general statistics using MTAG. National summary statistics using MTAG. National statistics using  $18$ 

16. Wendt FR, Pathak GA, Lencz T, Krystal JH, Gelernter J, Polimanti R (2021): Multivariate genome-

better health, and longer life. Mol Psychiatry. wide analysis of education, socioeconomic analysis of the analysis of the analysis of the status and the status<br>17. Hill WD, Weiss A, Liewald DC, Davies G, Porteous DJ, Hayward C, et al. (2019): Genetic<br>contributions to tw 17.<br>contr<br>bette<br>18. 17. A contributions to two special factors of neuroticism are associated with affluence, higher intelligent<br>better health, and longer life. *Mol Psychiatry*.<br>18. Eysenck HJ, Eysenck SBG (1975): *Manual of the Eysenck Perso* 

communions of two special factors of neuroticism are associated with anti-type intelligency<br>18. Eysenck HJ, Eysenck SBG (1975): Manual of the Eysenck Personality Questionnaire. London:<br>19. Smith DJ, Nicholl BI, Cullen B, M

better 18.<br>Better and Stoughton.<br>Hodder and Stoughton.<br>19. Smith DJ, Nicholl BI, Cullen B, Martin I.<br>Characteristics of Probable Major Depression. 19. Eystemmy System of Caser, Manual of the Eystem Personal, Questionnaire Ennance<br>19. Smith DJ, Nicholl BI, Cullen B, Martin D, Ul-Haq Z, Evans J, et al. (2013): Prevalence and<br>Characteristics of Probable Major Depression Hodder and Stoughton.<br>
19. Smith DJ, Nicholl BI, Cullen B, Martin D, UI-Haq Z, Evans J, et al. (2013): Prevalence and<br>
Characteristics of Probable Major Depression and Bipolar Disorder within UK Biobank: Cross-Sectic<br>
Stud 21. Characteristics of Probable Major Depression and Bipolar Disorder within UK Biobank: Cross-Se<br>20. Study of 172,751 Participants. *PLOS ONE*. 8:e75362.<br>20. Bycroft C, Freeman C, Petkova D, Band G, Elliott LT, Sharp K, e

21. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ (2015): Second-generation PLINK:<br>rising to the challenge of larger and richer datasets. Gigascience. 4:7. resource with deep phenotyping and genomic data. *Nature*. 562:203-209.<br>
21. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ (2015): Second-generation PLINK<br>
rising to the challenge of larger and richer data 20. By Exception Chemical Community Community Chemical Community Chemical Community Community Chemical Communi<br>21. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ (2015): Second-generation PL<br>22. Gao F, Chan

Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ (2015<br>rising to the challenge of larger and richer datasets. *Gigascience*. 4:7.<br>22. Gao F, Chang D, Biddanda A, Ma L, Guo Y, Zhou Z, et al. (2015): XW<br>Genetic The change of larger and richer datasets. Gigascience. 4:7.<br>22. Gao F, Chang D, Biddanda A, Ma L, Guo Y, Zhou Z, et al. (2015): XWAS: A Software Toolset for<br>3. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bende

CREAT CRAIN AT A HOT CREAT CRAIN CRAIN CRAIN CRAIN CRAIN CRIPTION OF CHAIN CRAIN<br>Tenetic Data Analysis and Association Studies of the X Chromosome.<br>23. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Ben<br>24. Chai Genetic Data Analysis and Association Studies of the X Chromosome. Journal of Heredity. 106:666-671<br>23. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. (2007): PLINK: a too<br>set for whole-genome as Central Analysis and Dentalysis and Association Studies of the X Christian Analysis and Association Studies of<br>Studies of the X Chois Studies of the Association and population-based linkage analyses. Am J Hum Genet. 81:559

23. Purcell S, Neale B, Neale B, Neale B, Neale B, Percharm, Percharm, Percharm, Percharm, Percharm B 23.<br>24. Choi SW, O'Reilly PF (2019): PRSice-2: Polygenic Risk Score software for biobank-scale data.<br>35 Gigascience. 8.<br>

set for the general and population and population and population-based analyses for biobank-scale data.<br>Gigascience. 8.<br>25. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al. (2015): LD Score<br>regr 24. Choi SW, O'Reilly PF (2019): PRSice-2: Polygenic Risk Score software for biobank-scale data.<br>Gigascience. 8.<br>25. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, et al. (2015): LD Score<br>regression S<br>25. Bulik-Sune<br>regression distin<br>47:291-295.<br>26. Finucar

23. Bullivan Bullivan BK, London, Amalaman, Alpha By Patterson, Patterson, 2014, 2015, 2017<br>1991-295.<br>26. Finucane HK, Bulik-Sullivan B, Gusev A, Trynka G, Reshef Y, Loh PR, et al. (2015): Partitionin<br>1991-1998 1995. regression distinguished conformating from polygenicity in genome-wide association studies. Partitioning<br>26. Finucane HK, Bulik-Sullivan B, Gusev A, Trynka G, Reshef Y, Loh PR, et al. (2015): Partitioning<br>27. Carol S. Marg 26. Finu<br>heritability b<br>47:1228-123<br>27. Gaza 27. Final B, Marquez-Luna C, Finucane HK, Price AL (2019): Reconciling S-LDSC and LDAK function<br>27. Gazal S, Marquez-Luna C, Finucane HK, Price AL (2019): Reconciling S-LDSC and LDAK function<br>28. Mondt EB, Bathak GA, Quess

17:1228-1235.<br>27. Gazal S, Marquez-Luna C, Finucane HK, Price AL (2019): Reconciling S-LDSC and LDAK functional annotation<br>28. Wendt FR, Pathak GA, Overstreet C, Tylee DS, Gelernter J, Atkinson EG, et al. (2021):<br>Character

Gazal S, Marquez-Luna C, Finucane HK, Price AL (2019): Reconciling S-LDSC and LDAK functional<br>enrichment estimates. *Nat Genet*. 51:1202-1204.<br>28. Wendt FR, Pathak GA, Overstreet C, Tylee DS, Gelernter J, Atkinson EG, et a 22. Gazal S, Marquez-Luna C, Marchine MA, Michael (2022), Machinange 22. Channel Machinesian<br>
28. Wendt FR, Pathak GA, Overstreet C, Tylee DS, Gelernter J, Atkinson EG, et al. (2021):<br>
Characterizing the effect of backgrou enrichment estimates find estimates. The serverse set of<br>28. Wendt FR, Pathak GA, Overstreet C, Tylee<br>Characterizing the effect of background selection<br>113:111-119. 28. Characterizing the effect of background selection on the polygenicity of brain-related traits. (2021)<br>113:111-119.<br>19  $\begin{array}{c} 113:111\text{-}119. \end{array}$   $\begin{array}{c} \text{13} \end{array}$ 

2022. Watanabe K, Umicevic Mirkov M, de Leeuw CA, van den Heuvel MP, Posthuma D (2019)<br>29. Watanabe K, Umicevic Mirkov M, de Leeuw CA, van den Heuvel MP, Posthuma D (2019)<br>31. Ge T, Chen CY, Ni Y, Feng YA, Smoller JW (2019

annotation of genetic associations with FUMA. Nat Commun. 8:1826.<br>
30. Watanabe K, Umicevic Mirkov M, de Leeuw CA, van den Heuvel MP, Posthuma D (2019):<br>
Genetic mapping of cell type specificity for complex traits. Nat Com Senetic mapping of cell type specificity for complex traits. Nat Commun. 10:3222.<br>31. Ge T, Chen CY, Ni Y, Feng YA, Smoller JW (2019): Polygenic prediction via Bayesian regress<br>32. Dennis JK, Sealock JM, Straub P, Lee YH,

Ge T, Chen CY, Ni Y, Feng YA, Smoller JW (2019): Polygenic prediction via B<br>and continuous shrinkage priors. Nat Commun. 10:1776.<br>32. Dennis JK, Sealock JM, Straub P, Lee YH, Hucks D, Actkins KE, et al. (2021):<br>test-wide a 32. General Shrinkage priors. Nat Commun. 10:1776.<br>32. Gennis JK, Sealock JM, Straub P, Lee YH, Hucks D, Actkins KE, et al. (2021): Clinical laboratory<br>32. General region of polygenic scores identifies biomarkers of comple and complete prior of the VH, Hucks D,<br>The Continuous String Continuous String (13:6)<br>Medicine. 13:6.<br>The Community of a large analysis of a identified DNA biobank. 33. Bodie in the sealer of polygenic scores identifies biomarkers of complex disease. *Genome*<br>Medicine. 13:6.<br>33. Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balser JR, et al. (2008):<br>Development of a large-s

Medicine. 13:6.<br>
13. Roden DM, Pulley JM, Basford MA, Bernard GR, Clayton EW, Balser JR, et al. (2008):<br>
Development of a large-scale de-identified DNA biobank to enable personalized medicine. Clin<br>
Pharmacol Ther. 84:362-33. Roden D<br>Development of<br>*Pharmacol Ther*<br>34. Wu P, G Superior Development of a large-scale de-identified DNA biobank to enable personalized medicine. Container SA. Wu P, Giffo

Pharmacol Ther. 84:362-369.<br>
Wu P, Gifford A, Meng X, Li X, Campbell H, Varley T, et al. (2019): Mapping ICD-10 and I<br>
CM Codes to Phecodes: Workflow Development and Initial Evaluation. *JMIR Med Inform*. 7:e14<br>
35. Gusev Manuscrich Pharmacol There.<br>24. Mull P, Gifford A, Men.<br>25. Gusev A, Ko A, Shi H,<br>36. Mang UL Kawasawa Y

35. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, et al. (2016): Integrative approaches for<br>1976. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, et al. (2016): Integrative approaches for<br>1974. James Lang H, Ka Codes to A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, et al. (2016): Integrative approaches to a large-scale transcriptome-wide association studies. Nat Genet. 48:245-252.<br>36. Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X,

35. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW, et al. (2016): Integrative approaches for<br>large-scale transcriptome-wide association studies. *Nat Genet*. 48:245-252.<br>36. Kang HJ, Kawasawa YI, Cheng F, Zhu Y, Xu X

large-scale transcriptome-wide association study of educational space the human brain. Nature. 478:483-489.<br>17. Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M, et al. (20<br>18. Lee JJ, Wedow R, Okbay A, Kong E, Maghz 37. Lee JJ, Wedow R, Okbay A, Kong E, Maghzian O, Zacher M, et al. (2018): Gene discovery and<br>polygenic prediction from a genome-wide association study of educational attainment in 1.1 million<br>individuals. Nat Genet. 50:11 the human brain. The human brain is the human brain.<br>27. Lee JJ, Wedow R, Okbay A, Kong<br>polygenic prediction from a genome-wide<br>individuals. Nat Genet. 50:1112-1121.<br>38. Gelernter J, Sun N, Polimanti R,

37. Lee Hy Telectrich, Emery A, Anagoliaan O, Zacher My 21. My 21. Hy 21. My 21. My 21. My 21. My 21. My 21. My<br>28. Coloration from a genome-wide association study of educational attainment in 1.1 million<br>38. Gelernter J, polygenic prediction from a general solution individuals. Nat Gener. 50:1112-1121.<br>
38. Gelernter J, Sun N, Polimanti R, Pietrzak R, Levey DF, Bryois J, et al. (2019): Genome-wide<br>
association study of post-traumatic stres 38. Gelernter J, Sun N, Polimanti R<br>association study of post-traumatic str<br>N*at Neurosci*. 22:1394-1401.<br>39. Stein MB, Levey DF, Cheng Z, N<br>association analyses of nost traumatio

38. Sociation study of post-traumatic stress disorder reexperiencing symptoms in >165,000 US vete<br>
Nat Neurosci. 22:1394-1401.<br>
39. Stein MB, Levey DF, Cheng Z, Wendt FR, Harrington K, Pathak GA, et al. (2021): Genome-v<br>
a ast Christmas Care in Manham Care are transferred protons of population stress disorder and its symptom subdomains in the Million<br>association analyses of post-traumatic stress disorder and its symptom subdomains in the Mil 39. Stein MB, Levey DF, C<br>association analyses of post-t<br>Veteran Program. *Nature Ger*<br>40. Power RA, Pluess M ( 39. Stein Mathematic Stress disorder and its symptom subdomains in the Million<br>Veteran Program. Nature Genetics. 53:174-184.<br>40. Power RA, Pluess M (2015): Heritability estimates of the Big Five personality traits based on

Veteran Program. Nature Genetics. 53:174-184.<br>40. Power RA, Pluess M (2015): Heritability estimates of the Big Five personality traits based common genetic variants. Translational Psychiatry. 5:e604-e604.<br>41. Tørring PM, L Veteran Program. *Nature Genetics.* 53:174-184.<br>40. Power RA, Pluess M (2015): Heritability estimates of the Big Five personality traits based on<br>common genetic variants. *Translational Psychiatry*. 5:e604-e604.<br>41. Tørrin

14. Common genetic variants. *Translational Psychiatry*. 5:e604-e604.<br>41. Tørring PM, Larsen MJ, Brasch-Andersen C, Krogh LN, Kibæk M, Laulund L, et al. (2019): Is<br>MED13L-related intellectual disability a recognizable synd MED13L-related intellectual disability a recognizable syndrome? *Eur J Med Genet*. 62:129-136.<br>20 41. MED13L-related intellectual disability a recognizable syndrome? *Eur J Med Genet*. 62:129-136.<br>20 MED13L-related intellectual disability a recognizable syndrome? Eur J Med Genet. 62:129-136.

12. Strawbridge RJ, Ward J, Ferguson J, Ferman N, Ferman J, Ferman J, Ferman Lincoln, 2019, Numman and polygenic association with completed suicide. *EBioMedicine*. 41:517-525.<br>43. Wendt FR, Pathak GA, Levey DF, Nuñez YZ, novel genome-minority and particularly in Entertaining generator that the pyramatic<br>disorders and polygenic association with completed suicide. *EBioMedicine*. 41:517-525.<br>43. Wendt FR, Pathak GA, Levey DF, Nuñez YZ, Overs disorders and polygens are in the set of the Wendt FR, Pathak GA, Levey DF, Nuñez YZ, Overstreet C, Tyrrell C, et al. (2021):<br>gene-by-environment genome-wide interaction study of trauma, posttraumatic-stress, a<br>Neurobiol S

gene-by-environment genome-wide interaction study of trauma, posttraumatic-stress, and suicidality<br>Neurobiol Stress. 14:100309.<br>44. Deneault E, Faheem M, White SH, Rodrigues DC, Sun S, Wei W, et al. (2019): CNTN5(-)(/+)or<br> genera, announceme-wide interaction study of trauma, posttraumatic stress, and suitendinary.<br>
Neurobiol Stress. 14:100309.<br>
44. Deneault E, Faheem M, White SH, Rodrigues DC, Sun S, Wei W, et al. (2019): CNTN5(-)(/+)or<br>
EHM 44. Deneault E, Faheem I<br>EHMT2(-)(/+)human iPSC-der<br>networks. *Elife*. 8.<br>45. Camacho-Arroyo I, Pi

44. Deneault E, Faheem M, Thinks Su, The M, Bangare B, Fahre, The M, Sun (2021). Channel, N, The<br>EHMT2(-)(/+)human iPSC-derived neurons from individuals with autism develop hyperactive neurona<br>networks. Elife. 8.<br>45. Camac EHMT2(1), Johnson iPSC-derived neurons from individuals with automorphyperactic individuals<br>
AB. Camacho-Arroyo I, Piña-Medina AG, Bello-Alvarez C, Zamora-Sánchez CJ (2020): Chapter Sever<br>
Sex hormones and proteins involve 45. Camacho-<br>Sex hormones and<br>Academic Press, p<br>46. Edwards A

45. Sex hormones and proteins involved in brain plasticity. In: Litwack G, editor. *Vitamins and Hormones:*<br>Academic Press, pp 145-165.<br>46. Edwards AC, Aliev F, Bierut LJ, Bucholz KK, Edenberg H, Hesselbrock V, et al. (201 Sex hormones and proteins in the summaring plasticity, the sexuality of the mathematical Academic Press, pp 145-165.<br>
Edwards AC, Aliev F, Bierut LJ, Bucholz KK, Edenberg H, Hesselbrock V, et al. (2012): Genome-<br>
22:31-41. Academic Press, pp 145-165.<br>
Edwards AC, Aliev F, Bierut LJ, Bucholz KK, Edenberg H, Hesselbrock V, et al. (2012): Genome-<br>
wide association study of comorbid depressive syndrome and alcohol dependence. *Psychiatr Genet*.<br>

 $\epsilon$ ehert The American Journal of Hyman Constice 100.12.22 polygenic scores when derived from the UK Biobank and applied to 9 ancestry groups from the same<br>cohort. The American Journal of Human Genetics. 109:12-23.<br>48. Sirugo G. Williams SM. Tishkoff SA (2019): The Missing Diversi 47. Pr<br>polygenic<br>cohort. *Th*<br>48. Sii 47. Private F, Assembly genic scores when derived from the UK Biobank and applied to 9 ancestry groups from the same<br>cohort. The American Journal of Human Genetics. 109:12-23.<br>48. Sirugo G, Williams SM, Tishkoff SA (2019):

polygenic Scores Williams SM, Tishkoff SA (2019): The Missing Diversity in Human Genetic Studies. Correct Studies SM, Tishkoff SA (2019): The Missing Diversity in Human Genetic Studies. Correct 177:26-31.<br>177:26-31. Vasdev

contra the American Pantal of Journal of Human Genetics. 18.<br>177:26-31.<br>49. Vasdev N, Kumar A, Veeratterapillay R, Thorpe AC (20<br>prostatic hyperplasia: retrospective analysis of 166 men ident 177:26-31.<br>49. Simuse G, Kumar A, Veeratterapillay R, Thorpe AC (2013): Hematuria secondary to benign<br>prostatic hyperplasia: retrospective analysis of 166 men identified in a single one stop hematuria clinic.<br>Curr Urol. 6: 49. Vas<br>prostatic hy<br>Curr Urol. 6<br>50. Per 49. prostatic hyperplasia: retrospective analysis of 166 men identified in a single one stop hematuria c<br>
Curr Urol. 6:146-149.<br>
50. Perry LM, Hoerger M, Silberstein J, Sartor O, Duberstein P (2018): Understanding the dist

prostatic hyperplasia: retrospective analysis of 166 mention and a single one stop hematuria clinic.<br>
S0. Perry LM, Hoerger M, Silberstein J, Sartor O, Duberstein P (2018): Understanding the distressed<br>
prostate cancer pat Curr Urol. 6:146-149.<br>
50. Perry LM, Hoerger M, Silberstein J, Sartor O, Duberstein P (2018): Understanding the distressed<br>
51. Weuve J, Mendes de Leon CF, Bennett DA, Dong X, Evans DA (2014): The red cell distribution<br>
51

prostate cancer patient: Role of personality. Psychooncology. 27:810-816.<br>51. Weuve J, Mendes de Leon CF, Bennett DA, Dong X, Evans DA (2014): The red cell distribution<br>width and anemia in association with prevalent dement

proses and the cancer patient: Role of personality.<br>
1991 - Weuve J, Mendes de Leon CF, Bennett DA, Dong X, Evans DA (2014)<br>
1991 - Width and anemia in association with prevalent dementia. Alzheimer Dis A,<br>
1991 - Samaguch width and anemia in association with prevalent dementia. Alzheimer Dis Assoc Disord. 28:99-105.<br>52. Yamaguchi S, Hamano T, Oka T, Doi Y, Kajimoto S, Shimada K, et al. (2021): Mean corpuscular<br>hemoglobin concentration: an a Widter and an emission of the minimism.<br>
Salemoglobin concentration: an anemia parameter predicting cardiovascular disease in incident dia<br>
patients. *J Nephrol.*<br>
Salemoglobin With Adziewicz M (2015): Depressive disorders 52. *Samaguara, Hamano T, 2003, Happen 2, Shimada R, 2006* (2022), Mean corpuscular<br>hemoglobin concentration: an anemia parameter predicting cardiovascular disease in incident dialysis<br>patients. *J Nephrol.*<br>53. Just MJ, K

hemoglobin concentration an anemia parameter predicting cardiovation: an anemia parameters in injure<br>patients. J Nephrol.<br>53. Lust MJ, Kozakiewicz M (2015): Depressive disorders co-existing with Addison-Biermer anemia<br>case patients. *J Nephrol.*<br>53. Just MJ, Kozakiewicz M (2015): Depressive disorders co-existing with Addison-Biermer anemia -<br>case report. *Neuropsychiatr Dis Treat.* 11:1145-1148. 53. Just May 1993. Just May 1993. Just May 1993.<br>State M (2015): Depression-Big M (2015).<br>The Addison-Big M (2015): Department and M (2015). Department and many states of the M (2015). The M (2016) of the M (2015) of the M case report. Neuropsychiatr Dis Treat. 11:11<br>21:

54. Bahrami A, Michaelmin, J. A, Sinn, Cambri, Anama, Tay, Tay, Tay, Tay, Tay, Michaelmin<br>
34. Basociated with cognitive impairment in adolescent girls: A cross-sectional survey. Applied<br>
35. Lee H-S, Chao H-H, Huang W-T, Meuropsychology: Child. 9:165-171.<br>55. Lee H-S, Chao H-H, Huang W-T, Chen SC-C, Yang H-Y (2020): Psychiatric disorders ri<br>with iron deficiency anemia and association with iron supplementation medications: a nati<br>database a S5. Lee H-S, Chao H-H, Huang W<br>with iron deficiency anemia and asset<br>database analysis. *BMC Psychiatry*. 2<br>56. Sobrero A, Puglisi F, Guglielr with iron deficiency anemia and association with iron supplementation medications: a nationwide<br>database analysis. *BMC Psychiatry*. 20:216.<br>56. Sobrero A, Puglisi F, Guglielmi A, Belvedere O, Aprile G, Ramello M, et al. (

Minimum deficiency anemia and association minimum deppendentation medication with intermined<br>database analysis. *BMC Psychiatry*. 20:216.<br>56. Sobrero A, Puglisi F, Guglielmi A, Belvedere O, Aprile G, Ramello M, et al. (200

database analysis. *BMC Psychiatry*. 20:216.<br>
56. Sobrero A, Puglisi F, Guglielmi A, Belvedere O, Aprile G, Ramello M, et al. (2001): Fatigue: a main<br>
component of anemia symptomatology. *Semin Oncol*. 28:15-18.<br>
57. Hides somponent of anemia symptomatology. *Semin Oncol.* 28:15-18.<br>57. Hidese S, Saito K, Asano S, Kunugi H (2018): Association between iron-deficiency anemia and<br>depression: A web-based Japanese investigation. *Psychiatry and C* 

depression: A web-based Japanese investigation. Psychiatry and Clinical Neurosciences. 72:513-521.<br>58. Girgenti MJ, Wang J, Ji D, Cruz DA, Stein MB, Gelernter J, et al. (2021): Transcriptomic<br>organization of the human brai depression: A web-based Japanese investigation. Psychiatry and Clinical Neurosciences. 72:513-521.<br>58. Girgenti MJ, Wang J, Ji D, Cruz DA, Stein MB, Gelernter J, et al. (2021): Transcriptomic<br>organization of the human brai

depression: A web-based of the human brain in post-traumatic stress disorder. Nat Neurosci. 24:24-33.<br>
Levey DF, Stein MB, Wendt FR, Pathak GA, Zhou H, Aslan M, et al. (2021): Bi-ancestral<br>
depression GWAS in the Million V Statemary Constants, Constants of the human brain in post-traumatic stress disorder. Nat Neurosci. 24:24-33.<br>59. Levey DF, Stein MB, Wendt FR, Pathak GA, Zhou H, Aslan M, et al. (2021): Bi-ancestral<br>depression GWAS in the organization of the human brain in post-tranumation of the human brain in the human brain in the human brain i<br>depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individu<br>new therapeutic direc

depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals<br>new therapeutic directions. Nat Neurosci. 24:954-963.<br>60. Gaspar HA, Gerring Z, Hübel C, Middeldorp CM, Derks EM, Breen G, et al. depression Gaspar HA, Gerring Z, Hübel C, Middeldorp CM, Derks EM, Breen G, et al. (2019): Using genetic<br>drug-target networks to develop new drug hypotheses for major depressive disorder. Translational<br>Psychiatry. 9:117.<br>E new 1980.<br>1990. – Gaspar HA, Gerring Z, Hübel C, Middeldorp CM<br>1991. – Araly Marken directions. Natural Asychiatry. 9:117.<br>1992. – Kuwahara T, Inoue K, D'Agati VD, Fujimoto T, E

drug-target networks to develop new drug hypotheses for major depressive disorder. Translational<br>Fsychiatry. 9:117.<br>61. Kuwahara T, Inoue K, D'Agati VD, Fujimoto T, Eguchi T, Saha S, et al. (2016): LRRK2 and RAB7L1<br>coordin Bychiatry. 9:117.<br>61. Kuwahara T, Inoue K, D'Agati VD, Fujimoto T, Eguchi T, Saha S, et al. (2016): LRRK2 and RAB.<br>6. Coordinately regulate axonal morphology and lysosome integrity in diverse cellular contexts. Scienti.<br>6. Experience<br>
61. Kuwahara<br>
coordinately regul<br>
Reports. 6:29945.<br>
62. Hindley G,

For the fundamental T, Indiana, T, Inglate C, D, Fughera T, D, Eguchi T, Sahara T, Sahara T, D and Raby C, Beingfie<br>
Reports. 6:29945.<br>
62. Hindley G, Bahrami S, Steen NE, O'Connell KS, Frei O, Shadrin A, et al. (2021): Ch coordinately regulations of the coordinate axonal morphology and lysosome integrity.<br>
Financel more integrity in diverse cellular than the shared genetic determinants of bipolar disorder, schizophrenia and risk-taking. Tra F<br>
Reports. Hindley G,<br>
shared genetic det<br>
11:466.<br>
MacLeod I 62. Hindley G, Bahrami S, Steen NE, O'Connell KS, Frei O, Shadrin A, et al. (2021): Characterising the<br>shared genetic determinants of bipolar disorder, schizophrenia and risk-taking. *Transl Psychiatry*.<br>11:466. MacLeod DA

shared general determinants of bipolar disorder, schizophrenia and risk-taking. Transly, and the sychiatry.<br>
63. MacLeod DA, Rhinn H, Kuwahara T, Zolin A, Di Paolo G, McCabe BD, et al. (2013): RAB7L1<br>
interacts with LRRK2 63.<br>interact:<br>77:425-4<br>64. interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. Neuron<br>77:425-439.<br>64. Strom NI, Yu D, Gerring ZF, Halvorsen MW, Abdellaoui A, Rodriguez-Fontenla C, et al. (202<br>Genome-wide associ

interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk. *Neuron.*<br>77:425-439.<br>64. Strom NI, Yu D, Gerring ZF, Halvorsen MW, Abdellaoui A, Rodriguez-Fontenla C, et al. (2021<br>Genome-wide as 64. Strom NI, Yu D, Gerring ZF, Halvorsen MW, Abdellaoui A, Rodriguez-Fontenla C, et al. (2021):<br>Genome-wide association study identifies new locus associated with OCD.<br>medRxiv.2021.2010.2013.21261078.<br>65. Zhong J, Li S, Z

64. Strom NI, Yu D, Changely Material Milly, Material of, Managelet Chandina C, Californ (2022).<br>64. Strom Ni, 2021.2010.2013.21261078.<br>65. Zhong J, Li S, Zeng W, Li X, Gu C, Liu J, et al. (2019): Integration of GWAS and b General Material Coloring, Material Material Andrew Materia<br>General School (1991-2010): The School (1991-2010): School (1991-2010): Integration of G<br>identifies FLOT1 as a risk gene for major depressive disorder. Neuropsych 65. Zhong J, Li S, Zeng W, Li X, Gu<br>identifies FLOT1 as a risk gene for ma<br>. Frankrities FLOT1 as a risk gene for major depressive disorder. Neuropsychopharmacology. 44:154<br>22  $\begin{align} \mathbf{r}^2 = \mathbf{r}^2 + \mathbf{r}^2$ 

66. Reisinger SN, Kong E, Molz B, Humberg T, Sideromenos S, Cicvaric A, et al. (2019): Flotillin-1<br>
interacts with the serotonin transporter and modulates chronic corticosterone response. *Genes Brain*<br> *Behav*. 18:e12482.

Montoliu T, Hidalgo V, Salvador A (2020): Personality and Hypothalamic-Pituitary-Adrenal Axis

in Older Men and Women. Frontiers in Psychology. 11.<br>68. Cin D-d, Rizak J, Feng X-I, Yang S-c, Lü L-b, Pan<br>a possible mechanism underlying stress and depressive<br>69. Powers SI, Laurent HK, Gunlicks-Stoessel M, Ba a possible mechanism underlying stress and depressive behaviour. Scientific Reports. 6:30187.

Powers SI, Laurent HK, Gunlicks-Stoessel M, Balaban S, Bent E (2016): Depression and anxiety a possible mechanism underlying stress and depressive behaviour. Scientific Reports. 6:30187.<br>69. Depression and anxiety predict sex-specific cortisol responses to interpersonal stress. Psychoneuroendocrinology. 69:172-179 a possible mechanism underlying stress and depressive demonstrationality. The reports and a<br>formulation of the possible mechanism of the pressive behaviour. Settled and a<br>predict sex-specific cortisol responses to interper France C, Laurent H, Laurent, France Etchical M, Balaban S, Burne (2019). Depression and analysis,<br>predict sex-specific cortisol responses to interpersonal stress. Psychoneuroendocrinology. 69:172-179. predict sex-specific cortisol responses to interpersonal stress. Psychoneuroendocrinology. 69:172-179.

# FIGURES







Fig 2. PheWAS and LabWAS results. Manhattan plots of sex-stratified phenome-wide (PheWAS in panel A) and laboratory-wide association studies (LabWAS in panel B) of neuroticism polygenic scores in the Vanderbilt University Biobank (BioVU). Each data point represents a single phecode (PheWAS) or laboratory measurement (LabWAS) with sample sizes per data point provided in Tables S6 and S7. Abbreviations: RDW=red blood cell distribution width; Trigs: triglyceride concentration; URBC=urinary red blood cell count.



Fig 3. TWAS comparison. (A) Relationship between male and female frontal cortex TWAS Z-scores for all significant associations after multiple testing correction in either sex ( $P < 1.59 \times 10^{-5}$ ). Each data point is a single gene associated with neuroticism in either males or females. Purple lines indicate z-score of 0 (no association). The dashed grey line denotes the 1-to-1 relationship between males and females and the blue line shows the linear regression between sexes. Labeled genes (in red) are significantly associated with neuroticism in one sex but do not meet nominal significance in the other. (B) Sex-by-developmental stage effects on frontal cortex gene expression (error bars denote 95% confidence interval) from BrainSpan (36). Sample sizes per developmental stage are provided in Table S10. (C) Relationship between male and female frontal cortex TWAS Z-scores for all significant associations after multiple testing correction in either sex ( $P < 1.14 \times 10^{-5}$ ).

Table 1. Sex-specific risk loci for neuroticism in UK Biobank participants of European ancestry. Differences in effect size estimates between sexes were calculated using two-sided Z-tests (see Methods) for each locus (Table S1) meeting genome-wide significance  $(P < 5x10^{-8})$  in one sex and failing to reach nominal sign



\*Comprehensive SNP positional-mapping results are provided in Table S2.







# **BioVU Males**

20



**BioVU Females** 

## PheWAS Domain

- circulatory system  $\bullet$
- congenital anomalies  $\bullet$
- dermatologic
- digestive  $\bullet$
- endocrine/metabolic
- $\bullet$ genitouriry
- hematopoietic
- infectious diseases
- injuries & poisonings
- mental disorders  $\bullet$
- musculoskeletal
- neoplasms  $\bullet$
- neurological

 $\bullet$ 

- pregncy complications
- respiratory
- sense organs
- $\bullet$ symptoms



